Close Window
Aetna Aetna
Clinical Policy Bulletin:
Transcranial Magnetic Stimulation and Cranial Electrical Stimulation
Number: 0469


Policy

Aetna considers transcranial magnetic stimulation experimental and investigational because its value and effectiveness has not been established.  It is not covered for any indication, including the following (not an all-inclusive list):

  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Anxiety disorders
  • Auditory verbal hallucinations
  • Autism
  • Blepharospasm
  • Bulimia nervosa
  • Chronic pain
  • Depression
  • Dystonia
  • Fibromyalgia
  • Levodopa-induced dyskinesia
  • Migraine
  • Mood disorders
  • Neuropathic pain
  • Obsessive-compulsive disorder
  • Panic disorder
  • Parkinson disease
  • Post-stroke dysphagia
  • Schizophrenia
  • Smell and taste dysfunction (e.g., phantosmia and phantageusia)
  • Spasticity
  • Stroke treatment (e.g., motor impairment, post-stroke aphasia, and post-stroke hemiplegia)
  • Tourette syndrome
  • Tinnitus
  • Traumatic brain injury.

Aetna considers navigated transcranial magnetic stimulation experimental and investigational for motor function mapping and/or treatment planning of neurological diseases/disorders (e.g., epilepsy, and resection of brain tumors) because its value and effectiveness has not been established.

Aetna considers cranial electrical stimulation (also known as cerebral electrotherapy, craniofacial electrostimulation, electric cerebral stimulation, electrosleep, electrotherapeutic sleep, transcerebral electrotherapy, transcranial electrotherapy, as well as the Liss Body Stimulator that is used to treat alcoholism) experimental and investigational because its value and effectiveness has not been established.  It is not covered for any indication, including the following (not an all-inclusive list):

  • Alcoholism
  • Alzheimer's disease
  • Autism
  • Chemical dependency
  • Chronic pain
  • Dementia
  • Depression
  • Headaches
  • Fibromyalgia
  • Mood and sleep disturbances
  • Neuropathic pain
  • Parkinson disease
  • Stroke treatment (e.g., motor impairment, post-stroke aphasia, and post-stroke hemiplegia)
  • Traumatic brain injury
  • Visual rehabilitation.


Background

Transcranial magnetic stimulation (TMS) is a non-invasive method of induction of a focal current in the brain and transient modulation of the function of the targeted cerebral cortex.  This procedure entails placement of an electromagnetic coil on the scalp; high-intensity electrical current is rapidly turned on and off in the coil through the discharge of capacitors.  Depending on stimulation parameters (frequency, intensity, pulse duration, stimulation site), repetitive TMS (rTMS) to specific cortical regions can either increase or decrease the excitability of the affected brain structures.

Transcranial magnetic stimulation has been investigated in the treatment of various psychiatric disorders, especially depression.  This procedure is usually carried out in an outpatient setting.  In contrast to electroconvulsive therapy, TMS does not require anesthesia or analgesia.  Furthermore, it does not affect memory and usually does not cause seizures.  However, the available peer-reviewed medical literature has not established the effectiveness of rTMS in the treatment of major depression or any other psychiatric disorders.  More research is needed to ascertain the roles of various stimulation parameters of rTMS for its optimal outcome as well as its long-term effectiveness in the treatment of depression and other psychiatric disorders.

Martin et al (2003) conducted a systematic review of randomized controlled trials that compared rTMS with sham in patients with depression.  The authors concluded that current trials are of low quality and provide insufficient evidence to support the use of rTMS in the treatment of depression.  This is in accordance with the observations of Fitzgerald and colleagues (2002) who noted that TMS has a considerable role in neuropsychiatric research.  It appears to have considerable potential as a therapeutic tool in depression, and perhaps a role in several other disorders, although widespread application requires larger trials and establishment of sustained response, as well as Gershon et al (2003) who stated that TMS shows promise as a novel anti-depressant treatment.  Systematic and large-scale studies are needed to identify patient populations most likely to benefit and treatment parameters most likely to produce success.

A health technology assessment prepared for the Ontario Ministry of Health and Long-Term Care (2004) concluded: “Due to several serious methodological limitations in the studies (Level 2 to 4 evidence) that examined the effectiveness of rTMS in patients with MDD [major depressive disorder], to date, it is not possible to conclude that rTMS is effective or not effective for the treatment of MDD (treatment resistant or not treatment resistant MDD).”

Nemeroff (2007) stated that the role of non-pharmacological therapies such as electro-convulsive therapy (ECT), vagus nerve stimulation (VNS), deep brain stimulation (DBS), and TMS in the treatment of patients with severe depression remain active avenues of investigation.

A randomized clinical trial (RCT) conducted for the National Coordinating Centre for Health Technology Assessment found that ECT is a more effective and potentially cost-effective antidepressant treatment than 3 weeks of rTMS (McLoughlin et al, 2007).  A total of 46 patients with major depression were randomized to receive a 15-day course of rTMS (n = 24) or a course of ECT (n = 22).  One patient was lost to follow-up at end of treatment and another 8 at 6 months.  The end-of-treatment Hamilton Rating Scale for Depression (HRSD) scores were lower for ECT (95 % confidence interval (CI): 3.40 to 14.05, p = 0.002), with 13 (59 %) achieving remission compared with four (17 %) in the rTMS group (p = 0.005). However, HRSD scores did not differ between groups at 6 months.  Beck Depression Inventory-II (BDI-II), visual analogue mood scales (VAMS), and  Brief Psychiatric Rating Scale (BPRS) scores were lower for ECT at end of treatment and remained lower after 6 months.  Improvement in subjective reports of side-effects following ECT correlated with anti-depressant response.  There was no difference between the 2 groups before or after treatment on global measures of cognition.  The NCCHTA study also evaluated the comparative costs of ECT and rTMS.  The investigators reported that, although individual treatment session costs were lower for rTMS than ECT, the cost for a course of rTMS was not significantly different from that for a course of ECT as more rTMS sessions were given per course.  Service costs were not different between the groups in the subsequent 6 months but informal care costs were significantly higher for the rTMS group (p = 0.04) and contributed substantially to the total cost for this group during the 6-month follow-up period.  The investigators reported that there was also no difference in gain in quality adjusted life years (QALYs) for ECT and rTMS patients.  The report noted that analysis of cost-effectiveness acceptability curves demonstrated that rTMS has very low probability of being more cost-effective than ECT.

The Australian Medical Services Advisory Committee (MSAC, 2007) found insufficient evidence of rTMS to support funding.  The Australian MSAC considered the safety and effectiveness of rTMS for moderate to severe refractory treatment resistant depression compared to ECT and found evidence that rTMS is safe and less invasive than ECT.  However, MSAC also found limited evidence that rTMS may be less effective than ECT.

On October 8, 2008, the U.S. Food and Drug Administration (FDA) cleared for marketing via the 510(k) process the NeuroStar TMS (transcranial magnetic stimulation) Therapy system, which is specifically indicated for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from 1 prior anti-depressant medication at or above the minimal effective dose and duration in the current episode.  A treatment course usually consists of 6 weeks of 40-min sessions (5 days a week).  However, the evidence supporting NeuroStar's effectiveness is less clear than its safety profile.  The FDA cleared the NeuroStar based on data that found patients did modestly better when treated with TMS than when they received a sham treatment.  It was a study fraught with statistical questions that concerned the agency's own scientific advisers.  For a more clear answer, the National Institutes of Health has an independent study under way that tracks 260 patients (Associated Press, 2008).

Randomized, controlled studies of rTMS compared to sham treatment have produced conflicting results (O'Reardon et al, 2007; Avery et al, 2008; Mogg et al, 2008).

In a double-blind, multi-site study, O'Reardon et al (2007) examined if TMS over the left dorsolateral prefrontal cortex (DLPFC) is effective and safe in the acute treatment of major depression.  A total of 301 medication-free patients with major depression who had not benefited from prior treatment were randomized to active (n = 155) or sham TMS (n = 146) conditions.  Sessions were conducted 5 times per week with TMS at 10 pulses/sec, 120 % of motor threshold, 3,000 pulses/session, for 4 to 6 weeks.  Primary outcome was the symptom score change as assessed at week 4 with the Montgomery-Asberg Depression Rating Scale (MADRS).  Secondary outcomes included changes on the 17- and 24-item Hamilton Depression Rating Scale (HAMD) and response and remission rates with the MADRS and HAMD.  Active TMS was significantly superior to sham TMS on the MADRS at week 4 (with a post hoc correction for inequality in symptom severity between groups at baseline), as well as on the HAMD17 and HAMD24 scales at weeks 4 and 6.  Response rates were significantly higher with active TMS on all 3 scales at weeks 4 and 6.  Remission rates were approximately 2-fold higher with active TMS at week 6 and significant on the MADRS and HAMD24 scales (but not the HAMD17 scale).  Active TMS was well-tolerated with a low drop-out rate for adverse events (4.5 %) that were generally mild and limited to transient scalp discomfort or pain.  The authors concluded that TMS was effective in treating major depression with minimal side effects reported.

Avery and colleagues (2008) described the results of an open-label extension study of active TMS in medication-resistant patients with MDD who did not benefit from an initial course of therapy in a previously reported 6-week, RCT of active versus sham TMS.  Patients with DSM-IV-defined MDD were actively enrolled in the study from February 2004 through September 2005 and treated with left pre-frontal TMS administered 5 times per week at 10 pulses per second, at 120 % of motor threshold, for a total of 3,000 pulses/session.  The primary outcome was the baseline to endpoint change score on the MADRS.  In those patients who received sham in the preceding RCT (n = 85), the mean reduction in MADRS scores after 6 weeks of open-label active TMS was -17.0 (95 % CI: -14.0 to -19.9).  Further, at 6 weeks, 36 (42.4 %) of these patients achieved response on the MADRS, and 17 patients (20.0 %) remitted (MADRS score less than 10).  For those patients who received and did not respond to active TMS in the preceding randomized controlled trial (n = 73), the mean reduction in MADRS scores was -12.5 (95 % CI: -9.7 to -15.4), and response and remission rates were 26.0 % and 11.0 %, respectively, after 6 weeks of additional open-label TMS treatment.  The authors concluded that this open-label study provides further evidence that TMS is a safe and effective treatment of MDD.  Furthermore, continued active TMS provided additional benefit to some patients who failed to respond to 4 weeks of treatment, suggesting that longer courses of treatment may confer additional therapeutic benefit.

On the other hand, Mogg and co-workers (2008) noted that the effectiveness of rTMS for major depression is unclear.  These investigators performed a RCT comparing real and sham adjunctive rTMS with 4-month follow-up.  A total of 59 patients with major depression were randomly assigned to a 10-day course of either real (n = 29) or sham (n = 30) rTMS of the left DLPFC.  Primary outcome measures were the 17-item HAMD and proportions of patients meeting criteria for response (50 % reduction in HAMD) and remission (HAMD8) after treatment.  Secondary outcomes included mood self-ratings on Beck Depression Inventory-II and visual analog mood scales, Brief Psychiatric Rating Scale score, and both self-reported and observer-rated cognitive changes.  Patients had 6-week and 4-month follow-ups.  Overall, HAMD scores were modestly reduced in both groups but with no significant group x time interaction (p = 0.09) or group main effect (p = 0.85); the mean difference in HAMD change scores was -0.3 (95 % CI: -3.4 to 2.8).  At end-of-treatment time-point, 32 % of the real group were responders compared with 10 % of the sham group (p = 0.06); 25 % of the real group met the remission criterion compared with 10 % of the sham group (p = 0.2); the mean difference in HAMD change scores was 2.9 (95 % CI: -0.7 to 6.5).  There were no significant differences between the 2 groups on any secondary outcome measures.  Blinding was difficult to maintain for both patients and raters.  The authors concluded that adjunctive rTMS of the left DLPFC could not be shown to be more effective than sham rTMS for treating depression.

Demirtas-Tatlidede et al (2008) examined the impact of rTMS throughout the long course of MDD and the effectiveness of rTMS in the treatment of depressive relapses.  A total of 16 medication-free patients with refractory MDD (diagnosed according to DSM-IV) who initially had clinically significant anti-depressant responses to a 10-day course of 10-Hz rTMS were consecutively admitted to the protocol from 1997 to 2001 and were followed for 4 years.  The cohort was studied during a total of 64 episodes of depressive relapse.  Severity of depression was evaluated with the HAMD and the BDI prior to and after completion of each rTMS treatment course.  Clinically significant response was defined as a reduction in HAMD score of at least 50 %.  Safety was assessed by serial neurological examinations and neuropsychological evaluations.  Approximately 50 % of the patients individually sustained a clinically significant response to the repeated courses of rTMS; the mean +/- SD decrease in HAMD scores was 64.8 % +/- 12.6 % (p < 0.0001), and, in BDI scores, 60.4 % +/- 20.6 % (p < 0.0001).  Despite the lack of adjuvant anti-depressant medication, the mean interval between treatment courses was approximately 5 months, and the medication-free period ranged from 26 to 43 months.  Transcranial magnetic stimulation was well-tolerated, and evaluations regarding the safety of the repeated applications of rTMS revealed no findings of concern.  The authors concluded that repeated rTMS applications have demonstrated a reproducible anti-depressant effect in patients with refractory depression who initially showed a clinically significant benefit.  The duration of effect varied across patients, but benefits were sustained for a mean of nearly 5 months.  They stated that further studies with larger cohorts will be useful in determining the long-term effectiveness of rTMS maintenance therapy.

In a systematic review and meta-analysis, Lam and colleagues (2008) examined the effectiveness of rTMS for treatment-resistant depression (TRD).  The systematic review was conducted by identifying published RCTs of active rTMS, compared with a sham control condition in patients with defined TRD (i.e., at least 1 failed trial).  The primary outcome was clinical response as determined from global ratings, or 50 % or greater improvement on a rating scale.  Other outcomes included remission and standardized mean differences in end point scores.  Meta-analysis was conducted for absolute risk differences using random effects models.  Sensitivity and subgroup analyses were also conducted to explore heterogeneity and robustness of results.  A total of 24 studies (n = 1,092 patients) met criteria for quantitative synthesis.  Active rTMS was significantly superior to sham conditions in producing clinical response, with a risk difference of 17 % and a number-needed-to-treat of 6.  The pooled response and remission rates were 25 % and 17 %, and 9 % and 6 % for active rTMS and sham conditions, respectively.  Sensitivity and subgroup analyses did not significantly affect these results.  Drop-outs and withdrawals owing to adverse events were very low.  The authors concluded that for patients with TRD, rTMS appears to provide significant benefits in short-term treatment studies.  However, the relatively low response and remission rates, the short durations of treatment, and the relative lack of systematic follow-up studies suggested that further studies are needed before rTMS can be considered as a first-line monotherapy treatment for TRD.  This is in agreement with the observations of Daskalakis and colleagues as well as Loo and associates.  The former group of researchers (Daskalakis et al, 2008) stated that more studies are needed to address the current limitations of rTMS and to optimize the effectiveness of this promising therapeutic option in TRD.  The latter group of investigators (Loo et al, 2008) noted that long-term effects of repeated rTMS sessions are as yet unknown.  When given within recommended guidelines, the overall safety profile of rTMS is good, and supports its further development as a clinical treatment.  It is also interesting to note that Knapp and co-workers (2008) stated that ECT is more cost-effective than rTMS in the treatment of severe depression.

Demitrack and Thase (2009) studied the clinical significance of the treatment effects seen with TMS in pharmaco-resistant major depression in their recently completed studies by comparing these outcomes with the results reported in several large, comprehensive published reference data sets of anti-depressant medications studied in both treatment-responsive and treatment-resistant patient populations.  The efficacy of TMS reported in RCTs was comparable to that of anti-depressants studied in similarly designed registration trials and to the adjunctive use of atypical anti-psychotic medications in controlled trials of anti-depressant non-responders.  The authors noted that these data may be helpful in treatment-planning decisions when using TMS in clinical practice.

In a prospective, multi-site, randomized, active sham-controlled (1:1 randomization) trial, George et al (2010) examined if daily left pre-frontal rTMS safely and effectively treats major depressive disorder.  About 860 outpatients were screened, yielding 199 anti-depressant drug-free patients with unipolar non-psychotic major depressive disorder.  These researchers delivered rTMS to the left pre-frontal cortex at 120 % motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 mins (3,000 pulses per session) using a figure-eight solid-core coil.  Sham rTMS used a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.  In the intention-to-treat sample (n = 190), remission rates were compared for the 2 treatment arms using logistic regression and controlling for site, treatment resistance, age, and duration of the current depressive episode.  Patients, treaters, and raters were effectively masked.  Minimal adverse effects did not differ by treatment arm, with an 88 % retention rate (90 % sham and 86 % active).  Primary efficacy analysis revealed a significant effect of treatment on the proportion of remitters (14.1 % active rTMS and 5.1 % sham) (p = 0.02).  The odds of attaining remission were 4.2 times greater with active rTMS than with sham (95 % CI: 1.32 to 13.24).  The number needed to treat was 12.  Most remitters had low anti-depressant treatment resistance.  Almost 30 % of patients remitted in the open-label follow-up (30.2 % originally active and 29.6 % sham).  The authors concluded that the findings of this study suggested that daily left pre-frontal rTMS produced statistically significant and clinically meaningful anti-depressant therapeutic effects for unipolar depressed patients who are refractory to or intolerant of medications.

There are several limitations with the afore-mentioned study: (i) as a consequence of the extensive work in designing a sham system, which delayed the start of the trial, the study failed to enroll the projected 240 subjects suggested by the initial power analysis.  This power issue may be the reason why the treatment condition effect on remission rate in the fully adherent sample analysis was not statistically significant.  Treaters were able to guess randomization assignment better than chance, without much confidence, which was not explained by covarying for clinical benefit, (ii) although the treatment effect was statistically significant on a clinically meaningful variable (remission), the overall number of remitters and responders was less than one would like with a treatment that requires daily intervention for 3 weeks or more, and (iii) it is unclear how long the clinical benefit lasts once achieved.

Slotema et al (2010) examined if rTMS is effective for various psychiatric disorders.  A literature search was performed from 1966 through October 2008 using PubMed, Ovid Medline, Embase Psychiatry, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and PsycINFO.  The following search terms were used: transcranial magnetic stimulation, TMS, repetitive TMS, psychiatry, mental disorder, psychiatric disorder, anxiety disorder, attention-deficit hyperactivity disorder, bipolar disorder, catatonia, mania, depression, obsessive-compulsive disorder, psychosis, post-traumatic stress disorder, schizophrenia, Tourette's syndrome, bulimia nervosa, and addiction.  Data were obtained from randomized, sham-controlled studies of rTMS treatment for depression (34 studies), auditory verbal hallucinations (AVH, 7 studies), negative symptoms in schizophrenia (7 studies), and obsessive-compulsive disorder (OCD, 3 studies).  Studies of rTMS versus ECT (6 studies) for depression were meta-analyzed.  Standardized mean effect sizes of rTMS versus sham were computed based on pre-treatment versus post-treatment comparisons.  The mean weighted effect size of rTMS versus sham for depression was 0.55 (p < 0.001).  Monotherapy with rTMS was more effective than rTMS as adjunctive to anti-depressant medication.  Electro-convulsive therapy was superior to rTMS in the treatment of depression (mean weighted effect size -0.47, p = 0.004).  In the treatment of AVH, rTMS was superior to sham treatment, with a mean weighted effect size of 0.54 (p < 0.001).  The mean weighted effect size for rTMS versus sham in the treatment of negative symptoms in schizophrenia was 0.39 (p = 0.11) and for OCD, 0.15 (p = 0.52).  Side effects were mild, yet more prevalent with high-frequency rTMS at frontal locations.  While the authors concluded that it is time to provide rTMS as a clinical treatment method for depression, for auditory verbal hallucinations, and possibly for negative symptoms, they do not recommend rTMS for the treatment of OCD.  Furthermore, the authors also stated that "[a]lthough the efficacy of rTMS in the treatment of depression and AVH may be considered proven, the duration of the effect is as yet unknown.  Effect sizes were measured immediately after the cessation of rTMS treatment.  There are indications that the effects of rTMS may last for several weeks to months.  Future studies should assess symptom relief with longer follow-up periods to assess the cost-effectiveness of rTMS treatment, and to indicate its economic advantages and disadvantages .... Although rTMS cannot replace ECT in depressive patients, there may be subgroups in which rTMS can replace antidepressant medication".

The National Institute for Health and Clinical Excellence's interventional procedure overview of TMS for severe depression (2007) concluded that current evidence suggests there are no major safety concerns associated with TMS for severe depression, but there is no evidence that the procedure has clinically useful efficacy.  Thus, TMS should be performed only in the context of research studies.  Any future research should focus on factors including dose intensity, frequency and duration.  Furthermore, the Institute for Clinical Systems Improvement's guideline on major depression in adults in primary care (2008) stated that results of research studies to date on rTMS for the treatment of MDD have been inconsistent and inconclusive.

The BCBS Association's Medical Advisory Panel (BCBSA, 2009) concluded that the use of rTMS in the treatment of depression does not meet the TEC criteria.  The TEC assessment stated that an important limitation of the evidence is lack of information beyond the acute period of treatment.  The TEC assessment noted that most of the clinical trials of rTMS evaluate the outcomes at the point of the last rTMS treatment, between 1 and 4 weeks, and that very few studies evaluated patients beyond this time period.  Although meta-analyses are consistent with short-term antidepressant effects, the clinical significance of the effect is uncertain.  The TEC assessment stated that the large clinical trial of rTMS by O'Reardon et al (2007) that was reviewed in this assessment did not unequivocally demonstrate efficacy, as the principal endpoint was not statistically significant at 4 weeks, and some results were sensitive to the methods of analysis.  The TEC assessment stated that patients in whom rTMS is indicated are usually treated with a second course of antidepressant therapy.  The clinical trial by O'Reardon et al (2007), which was sham controlled without active treatment, can not determine whether rTMS would be more or less successful than this standard treatment.  Referring to the study by George et al (2010), the TEC assessment also noted that a clinical trial sponsored by the National Institute of Mental Health has recruited subjects for another clinical trial of rTMS; however, this trial also appears to have only a short duration (3 weeks) in which the participants are randomized to rTMS or sham before crossovers or alternative treatments are offered.

An assessment by the California Technology Assessment Forum (CTAF, 2009) of rTMS for treatment-resistant depression concluded that rTMS does not meet CTAF technology assessment criteria.  This report stated that there is insufficient evidence to conclude that rTMS improves net health outcomes for patients with treatment resistant depression, or that it is as effective as current alternatives (e.g., augmentation, ECT, or new drugs).  The report noted that many of the individual studies of rTMS for treatment-resistant depression randomized less than 20 patients and were under-powered to detect changes in net health outcomes, particularly remission of depression.  The CTAF assessment stated that the largest and most recent clinical trials of rTMS for depression failed to demonstrate significant improvements on their primary outcome measures.  The CTAF assessment noted, in addition, that there is no consensus on how to perform rTMS and a dearth of evidence on the efficacy of rTMS after cessation of therapy.  "Undoubtedly because of the evidence that treatment does have some clinical effect, there is active ongoing research into rTMS.  However, it is too early to conclude that rTMS improves net health outcomes for patients with treatment resistant depression, much less that it is as effective as current alternatives such as augmentation, new drugs, or ECT."

An assessment of rTMS by the Health Council of the Netherlands (2008) stated that efficacy studies should focus, in particular, on the use of rTMS to treat patients suffering from depression who are not responding well to medication.  The assessment stated that it would also be useful to study the longer term effects of rTMS therapy in depression.

An assessment of rTMS for depression by the Swedish Council on Technology Assessment in Health Care (SBU) (Brorrson et al, 2009) concluded that although the results of the studies are promising, they continue to regard the treatment as experimental.  The assessment noted that one issue is that it is not known to what extent the treatment is effective in drug-resistant depression.  The assessment also called for additional studies examining potential adverse effects of rTMS on memory.

An Agency for Healthcare Research and Quality's review (Gaynes et al, 2011) reported that there is insufficient evidence to evaluate whether non-pharmacological treatments are effective for TRD.  The review summarized evidence of the effectiveness of 4 non-pharmacological treatments: (i) ECT, (ii) rTMS, (iii) VNS, and (iv) cognitive behavioral therapy (CBT) or inter-personal psychotherapy.  With respect to maintaining remission (or preventing relapse), there were no direct comparisons (evidence) involving ECT, rTMS, VNS, or CBT.  With regard to indirect evidence, there were 3 fair trials compared rTMS with a sham procedure and found no significant differences, however, too few patients were followed during the relapse prevention phases in 2 of the 3 studies (20-week and 6-month follow-up) and patients in the 3rd study (3-month follow-up) received a co-intervention providing insufficient evidence for a conclusion.  There were no eligible studies for ECT, VNS. or psychotherapy.  The review concluded that that comparative clinical research on non-pharmacologic interventions in a TRD population is early in its infancy, and many clinical questions about efficacy and effectiveness remain unanswered.  Interpretation of the data is substantially hindered by varying definitions of TRD and the paucity of relevant studies.  The greatest volume of evidence is for ECT and rTMS.  However, even for the few comparisons of treatments that are supported by some evidence, the strength of evidence is low for benefits, reflecting low confidence that the evidence reflects the true effect and indicating that further research is likely to change our confidence in these findings.  This finding of low strength is most notable in 2 cases: ECT and rTMS did not produce different clinical outcomes in TRD, and ECT produced better outcomes than pharmacotherapy.  No trials directly compared the likelihood of maintaining remission for non-pharmacologic interventions.  The few trials addressing adverse events, subpopulations,subtypes, and health-related outcomes provided low or insufficient evidence of differences between non-pharmacologic interventions.  The most urgent next steps for research are to apply a consistent definition of TRD, to conduct more head-to-head clinical trials comparing non-pharmacologic interventions with themselves and with pharmacologic treatments, and to delineate carefully the number of treatment failures following a treatment attempt of adequate dose and duration in the current episode.

There is also a lack of scientific evidence in the use of TMS as a diagnostic tool for psychiatric disorders, and treatment for chronic pain.  Pridmore et al (2005) stated that in studies of TMS for the treatment of chronic pain, there is some evidence that temporary relief can be achieved in a proportion of sufferers.  Work to this point is encouraging, but systematic assessment of stimulation parameters is necessary if TMS is to attain a role in the treatment of chronic pain.  Furthermore, Canavero and Bonicalzi (2005) noted that TMS has no role in the management of patients with central pain, a major chronic pain syndrome.

In a double-blind, randomized, cross-over study, Andre-Obadia et al (2008) evaluated, against placebo, the pain-relieving effects of high-rate rTMS on neuropathic pain (n = 28).  The effect of a change in coil orientation (postero-anterior versus latero-medial) on different subtypes of neuropathic pain was further tested in a subset of 16 patients.  Pain relief was evaluated daily during 1 week.  High-frequency, postero-anterior rTMS decreased pain scores significantly more than placebo.  Postero-anterior rTMS also out-matched placebo in a score combining subjective (pain relief, quality of life) and objective (rescue drug intake) criteria of treatment benefit.  Changing the orientation of the coil from postero-anterior to latero-medial did not yield any significant pain relief.  The analgesic effects of postero-anterior rTMS lasted for approximately 1 week.  The pain-relieving effects were observed exclusively on global scores reflecting the most distressing type of pain in each patient.  Conversely, rTMS did not modify specifically any of the pain subscores that were separately tested (ongoing, paroxysmal, stimulus-evoked, or disesthesic pain).  The authors concluded that postero-anterior rTMS was more effective than both placebo and latero-medial rTMS.  When obtained, pain relief was not specific of any particular submodality, but rather reduced the global pain sensation whatever its type.  Moreover, they stated that these findings were driven from a small number of subjects; thus they need to be replicated.

Funak and colleagues (2006) noted that in healthy volunteers (HV), 1 session of 1-Hz rTMS over the visual cortex induces dishabituation of visual evoked potentials (VEPs) on average for 30 mins, while in migraineurs 1 session of 10-Hz rTMS replaces the abnormal VEP potentiation by a normal habituation for 9 mins.  These investigators examined if repeated rTMS sessions (1-Hz in 8 HV; 10-Hz in 8 migraineurs) on 5 consecutive days can modify VEPs for longer periods . In all 8 HV, the 1-Hz rTMS-induced dishabituation increased in duration over consecutive sessions and persisted between several hours (n = 4) and several weeks (n = 4) after the 5th session.  In 6 of the 8 migraineurs, the normalization of VEP habituation by 10-Hz rTMS lasted longer after each daily stimulation, but did not exceed several hours after the last session, except in 2 patients, where it persisted for 2 days and 1 week.  The authors concluded that daily rTMS can thus induce long-lasting changes in cortical excitability and VEP habituation pattern.  However, whether this effect may be useful in preventing migraines remains to be determined.

Wagle-Shukla et al (2007) examined the effectiveness of rTMS for the treatment of patients (n = 6) with levodopa-induced dyskinesias (LID).  They reported that a 2-week course of low-frequency rTMS reduced LID as indexed by both objective as well as subjective evaluations, with no change in parkinsonism as evaluated by Unified Parkinson Disease Rating Scale motor scores.  The benefit was observed at 1 day after treatment, but not 2 weeks later.  The drawbacks of this study were its small sample size and the open labeled design.  Furthermore, benefits were not sustained.  More research is needed to ascertain the clinical value, if any, of rTMS in the treatment of LID.

An assessment of rTMS by the Health Council of the Netherlands (2008) stated that the use of rTMS to treat patients with Parkinson’s disease has produced some encouraging results, and that this technology could be useful in identifying the best site for deep brain stimulation.  The assessment stated that it is "still open to question" whether or not rTMS has the potential to reduce tremors.

In a pilot study, Smith et al (2007) evaluated the effectiveness of rTMS and its effects on attentional deficits and cortical asymmetry in 4 patients with chronic tinnitus using objective and subjective measures and employing an optimization technique refined in our laboratory.  Patients received 5 consecutive days of active, low-frequency rTMS or sham treatment (using a 45-degree coil-tilt method) before crossing over.  Subjective tinnitus was assessed at baseline, after each treatment, and 4 weeks later.  Positron emission tomography/computed tomography (PET/CT) scans were obtained at baseline and immediately after active treatment to examine change in cortical asymmetry.  Attentional vigilance was assessed at baseline and after each treatment using a simple reaction time test.  All patients had a response to active (but not sham) rTMS, as indicated by their best tinnitus ratings; however, tinnitus returned in all patients by 4 weeks after active treatment.  All patients had reduced cortical activity visualized on PET immediately after active rTMS.  Mean reaction time improved (p < 0.05) after active but not sham rTMS.  The authors concluded that rTMS is a promising treatment modality that can transiently diminish tinnitus in some individuals, but further trials are needed to determine the optimal techniques required to achieve a lasting response.  This is in agreement with the findings of Plewnia et al (2007) who reported that the effects of rTMS for patients with chronic tinnitus are only moderate; inter-individual responsiveness varied; and the attenuation of tinnitus appeared to wear off within 2 weeks after the last stimulation session.

In a pilot study, Lee and colleagues (2008) examined if rTMS may suppress excessive spontaneous activity in the left superior temporal gyrus associated with tinnitus.  A total of 8 patients with tinnitus received 5 consecutive days of rTMS (0.5 Hz, 20 mins) to the left temporo-parietal area.  Tinnitus Handicap Inventory (THI) measures before sessions 1 and 3 and after session 5 were used to evaluate effectiveness.  Patient 1's THI decreased 40 to 34 to 26, patient 4 reported a subjective improvement, patient 8 withdrew, and the remaining patients reported no improvement.  Adverse effects included temporary soreness, restlessness, and photophobia.  The authors concluded that the parameters for this rTMS study are different from those that reported success with its use. W ith these current parameters, rTMS did not improve tinnitus.  There were no permanent adverse outcomes.

Kleinjung et al (2009) investigated if administration of the dopamine precursor levodopa before low-frequency rTMS enhances its effectiveness in tinnitus treatment.  A total of 16 patients with chronic tinnitus received 100 mg of levodopa before each session of low-frequency rTMS.  Results were compared with a matched control group of 16 patients who received the same treatment, but without levodopa.  Treatment outcome was assessed with a standardized tinnitus questionnaire.  Both stimulation protocols resulted in a significant reduction of tinnitus scores after 10 days of stimulation; however, there was no significant difference between the 2 groups.  The authors concluded that these findings suggested that 100 mg of levodopa does not enhance the effect of rTMS in the treatment of tinnitus.  Furthermore, they stated that "[e]ven if the available data clearly demonstrate the therapeutic potential of rTMS in tinnitus, the clinical effects are still relatively limited.  A better understanding of the underlying neurobiological mechanisms will be crucial for optimizing stimulation protocols and further improving the efficacy of rTMS".

In a Cochrane review on rTMS for tinnitus, Meng et al (2011) concluded that there is very limited support for the use of low-frequency rTMS for the treatment of patients with tinnitus.  When considering the impact of tinnitus on patients' quality of life, support is from a single study with a low-risk of bias based on a single outcome measure at a single point in time.  When considering the impact on tinnitus loudness, this is based on the analysis of pooled data with a large confidence interval.  Studies suggest that rTMS is a safe treatment for tinnitus in the short-term, however there were insufficient data to provide any support for the safety of this treatment in the long-term.  The authors stated that more prospective, randomized, placebo-controlled, double-blind studies with large sample sizes are needed to confirm the effectiveness of rTMS for tinnitus patients.  Uniform, validated, tinnitus-specific questionnaires and measurement scales should be used in future studies.

Prasko et al (2007) examined if rTMS would facilitate effect of serotonin reuptake inhibitors (SRIs) in patients with panic disorder (n = 15).  Patients suffering from panic disorder resistant to SRI therapy were randomly assigned to either active or to sham rTMS.  The objective of the study was to compare the 2- and 4-weeks effectiveness of the 10 sessions low-frequency rTMS with sham rTMS add on SRI therapy.  These researchers used 1-Hz, 30-min rTMS, 110 % of motor threshold administered over the right dorso-lateral prefrontal cortex (DLPFC).  The same time schedule was used for sham administration.  Psychopathology was evaluated by means of the rating scales CGI, HAMA, PDSS and BAI before the treatment, immediately after the experimental treatment, and 2 weeks after the experimental treatment by an independent reviewer.  Both groups improved during the study period but the treatment effect did not differ between groups in any of the instruments.  The authors concluded that low-frequency rTMS administered over the right dorso-lateral prefrontal cortex after 10 sessions did not differ from sham rTMS add on SRIs in patients with panic disorder.

Rossini and Rossi (2007) stated that TMS is widely used in clinical neurophysiology, including rehabilitation and intra-operative monitoring.  Single-pulse TMS and other more recent versions (e.g., paired-pulse TMS, rTMS, integration with structural and functional MRI, and neuro-navigation) allow motor output to be mapped precisely to a given body district.  Moreover, TMS can be used to assess excitatory/inhibitory intra-cortical circuits and to provide information on brain physiology and pathophysiology of various neuropsychiatric diseases as well as on the mechanisms of brain plasticity and of neuroactive drugs.  Transcranial magnetic stimulation applied over non-motor areas made it possible to extend research applications in several fields of psychophysiology.  Being able to induce relatively long-lasting excitability changes, rTMS has made the treatment of neuropsychiatric diseases linked with brain excitability dysfunctions possible.  The authors noted that these uses, however, warrant further large-scale studies.  In emerging fields of research, TMS-EEG co-registration is considered a promising approach to evaluate cortico-cortical connectivity and brain reactivity with high temporal resolution.  However, safety and ethical limitations of TMS technique need a high level of vigilance.

Centonze and associates (2007) examined if investigate rTMS can modify spasticity.  These researchers used high-frequency (5 Hz) and low-frequency (1 Hz) rTMS protocols in 19 remitting patients with relapsing-remitting multiple sclerosis and lower limb spasticity.  A single session of 1 Hz rTMS over the leg primary motor cortex increased H/M amplitude ratio of the soleus H reflex, a reliable neurophysiologic measure of stretch reflex.  Five hertz rTMS decreased H/M amplitude ratio of the soleus H reflex and increased cortico-spinal excitability.  Single sessions did not induce any effect on spasticity.  A significant improvement of lower limb spasticity was observed when rTMS applications were repeated during a 2-week period.  Clinical improvement was long-lasting (at least 7 days after the end of treatment) when patients underwent 5 Hz rTMS treatment during a 2-week protocol.  No effect was obtained after a 2-week sham stimulation. The authors concluded that rTMS may improve spasticity in multiple sclerosis.  The findings of this study need to be validated by prospective RCTs with larger patient numbers.

Pigot and colleagues (2008) noted that rTMS has also been investigated for the treatment of some anxiety disorders (e.g., obsessive-compulsive disorder, post-traumatic stress disorder and panic disorder).  While anecdotal reports and open studies have suggested a therapeutic role for rTMS in anxiety disorders, controlled studies, which have varied greatly in terms of rTMS administration, have not shown it to be superior to placebo.  Furthermore, reports in animal models of anxiety have not been consistent.  Thus, there is currently no convincing evidence for the clinical role of rTMS in the treatment of anxiety disorders.  The authros stated that more research is needed, drawing on advances in the understanding of pathological neurocircuitry in anxiety disorders and the mechanisms of action by which rTMS may alter that neurocircuitry.  In a review on OCD, Abramowitz and colleagues (2009) stated that although rTMS has not been extensively assessed in this disorder, available data do not support its therapeutic efficacy for this condition.

In a single-center, randomized, double-blind, sham-controlled study, Walpoth et al (2008) examined the effects of rTMS in bulimia nervosa (BN).  A total of 14 women meeting DSM-IV criteria for BN were included in the study.  In order to exclude patients highly responsive to placebo, all patients were first submitted to a 1-week sham treatment.  Randomization was followed by 3 weeks of active treatment or sham stimulation.  The main outcome was the change in binges and purges.  Secondary outcome variables were the decrease of the Hamilton Depression Rating Scale (HDRS), the Beck Depression Inventory (BDI) and the Yale-Brown Obsessive Compulsive Scale (YBOCS) over time.  The average number of binges per day declined significantly between baseline and the end of treatment in the 2 groups.  There was no significant difference between sham and active stimulation in terms of purge behavior, BDI, HDRS and YBOCS over time.  The authors concluded that these preliminary results indicated that rTMS in the treatment of BN does not exert additional benefit over placebo.

Freitas and colleagues (2009) performed meta-analyses of all prospective studies of the therapeutic application of rTMS in refractory schizophrenia assessing the effects of high-frequency rTMS to the left dorsolateral prefrontal cortex (DLPFC) to treat negative symptoms, and low-frequency rTMS to the left temporo-parietal cortex (TPC) to treat auditory hallucinations (AH) and overall positive symptoms.  When analyzing controlled (active arms) and uncontrolled studies together, the effect sizes showed significant and moderate effects of rTMS on negative and positive symptoms (based on PANSS-N or SANS, and PANSS-P or SAPS, respectively).  However, the analysis for the sham-controlled studies revealed a small non-significant effect size for negative (0.27, p = 0.417) and for positive symptoms (0.17, p = 0.129).  When specifically analyzing AH (based on AHRS, HCS or SAH), the effect size for the sham-controlled studies was large and significant (1.04; p = 0.002).  The authors concluded that these meta-analyses support the need for further controlled, larger trials to assess the clinical efficacy of rTMS on negative and positive symptoms of schizophrenia, while suggesting the need for exploration for alternative stimulation protocols.

An assessment by the Health Council of the Netherlands (2008) stated that studies of rTMS for hallucinations in schizophrenic patients are both fewer in number and more restricted in scope than in the case of depression.

Khedr et al (2009a) examined the therapeutic effect of rTMS on post-stroke dysphagia.  A total of 26 patients with post-stroke dysphagia due to mono-hemispheric stroke were randomly allocated to receive real (n = 14) or sham (n = 12) rTMS of the affected motor cortex.  Each patient received a total of 300 rTMS pulses at an intensity of 120 % hand motor threshold for 5 consecutive days.  Clinical ratings of dysphagia and motor disability were assessed before and immediately after the last session and then again after 1 and 2 months.  The amplitude of the motor-evoked potential (MEP) evoked by single-pulse TMS was also assessed before and at 1 month in 16 of the patients.  There were no significant differences between patients who received real rTMS and the sham group in age, hand grip strength, Barthel Index or degree of dysphagia at the baseline assessment.  Real rTMS led to a significantly greater improvement compared with sham in dysphagia and motor disability that was maintained over 2 months of follow-up.  This was accompanied by a significant increase in the amplitude of the esophageal MEP evoked from either the stroke or non-stroke hemisphere.  The authors concluded that rTMS may be a useful adjunct to conventional therapy for dysphagia after stroke.  These findings need to be validated by well-designed studies.

Regarding the use of rTMS in stroke, the Health Council of the Netherlands (2008) found that few articles have been published on this topic, and that this limited amount of published data reveals only short-term, marginal improvements.

Avenanti et al (2012) examined the long-term behavioral and neurophysiologic effects of combined time-locked rTMS and physical therapy (PT) intervention in chronic stroke patients with mild motor disabilities.  A total of 30 patients were enrolled in a double-blind, randomized, single-center clinical trial.  Patients received 10 daily sessions of 1 Hz rTMS over the intact motor cortex.  In different groups, stimulation was either real (rTMS(R)) or sham (rTMS(S)) and was administered either immediately before or after PT.  Outcome measures included dexterity, force, inter-hemispheric inhibition, and corticospinal excitability and were assessed for 3 months after the end of treatment.  Treatment induced cumulative rebalance of excitability in the 2 hemispheres and a reduction of inter-hemispheric inhibition in the rTMS(R) groups.  Use-dependent improvements were detected in all groups.  Improvements in trained abilities were small and transitory in rTMS(S) patients.  Greater behavioral and neurophysiologic outcomes were found after rTMS(R), with the group receiving rTMS(R) before PT (rTMS(R)-PT) showing robust and stable improvements and the other group (PT-rTMS(R)) showing a slight improvement decline over time.  The authors concluded that these findings indicated that priming PT with inhibitory rTMS is optimal to boost use-dependent plasticity and rebalance motor excitability and suggest that time-locked rTMS is a valid and promising approach for chronic stroke patients with mild motor impairment. Furthermore, the authors stated that "[f]urther studies are needed to evaluate the effect of intervention order of time-locked rTMS in the same patients.  Moreover, future studies should assess whether the present findings can be extended to stroke patients with moderate to severe motor impairments".

Corti et al (2012) stated that conceptually rTMS could be used therapeutically to restore the balance of inter-hemispheric inhibition after stroke.  Repetitive TMS has been used in 2 ways: (i) low-frequency stimulation (less than or equal to 1 Hz) to the motor cortex of the unaffected hemisphere to reduce the excitability of the contralesional hemisphere or (ii) high-frequency stimulation (greater than 1 Hz) to the motor cortex of the affected hemisphere (AH) to increase excitability of the ipsilesional hemisphere.  These investigators reviewed evidence regarding the safety and effectiveness of high-frequency rTMS to the motor cortex of the AH.  The studies included investigated the concurrent effects of rTMS on the excitability of corticospinal pathways and upper-limb motor function in adults after stroke.  The findings of this review suggested that rTMS applied to the AH is a safe technique and could be considered an effective approach for modulating brain function and contributing to motor recovery after stroke.  The authors concluded that although the studies included in this review provided important information, double-blinded, sham-controlled phase II and phase III clinical trials with larger sample sizes are needed to validate this novel therapeutic approach.

In a review on the diagnosis of amyotrophic lateral sclerosis (ALS), Elman and McCluskey (2010) stated that rTMS remains a largely experimental technique and is not used routinely for clinical diagnosis.  In a Cochrane review on rTMS for the treatment of ALS or motor neuron disease, Guo et al (2011) concluded that there is currently insufficient evidence to draw conclusions about the safety and effectiveness of rTMS in the treatment of ALS.  They noted that further studies may be helpful if their potential benefit is weighed against the impact of participation in a RCT on people with ALS.

In a review on autism, Levy et al (2009) stated that biologically based treatments include anti-infectives, chelation medications, gastro-intestinal medications, hyperbaric oxygen therapy, off-label drugs (e.g., secretin), and intravenous immunoglobulins.  Non-biologically based treatments include auditory integration training, chiropractic therapy, cranio-sacral manipulation, facilitated communication, interactive metronome, and transcranial stimulation.  However, few studies have addressed the safety and effectiveness of most of these treatments.

Guse et al (2010) stated that TMS was introduced as a non-invasive tool for the investigation of the motor cortex.  The repetitive application (rTMS), causing longer lasting effects, was used to study the influence on a variety of cerebral functions.  High-frequency (greater than 1 Hz) rTMS is known to depolarize neurons under the stimulating coil and to indirectly affect areas being connected and related to emotion and behavior.  Researchers found selective cognitive improvement after high-frequency (HF) stimulation specifically over the left dorso-lateral pre-frontal cortex (DLPFC).  These researchers performed a systematic review of HF-rTMS studies (1999 to 2009) stimulating over the prefrontal cortex of patients suffering from psychiatric/neurological diseases or healthy volunteers, where the effects on cognitive functions were measured.  The cognitive effect was analyzed with regard to the impact of clinical status (patients/healthy volunteers) and stimulation type (verum/sham).  Repetitive TMS at 10, 15 or 20 Hz, applied over the left DLPFC, within a range of 10 to 15 successive sessions and an individual motor threshold of 80 to 110 %, is most likely to cause significant cognitive improvement.  In comparison, patients tend to reach a greater improvement than healthy participants.  Limitations concern the absence of healthy groups in clinical studies and partly the absence of sham groups.  Thus, future investigations are needed to assess cognitive rTMS effects in different psychiatric disorders versus healthy subjects using an extended standardized neuropsychological test battery.  Since the pathophysiological and neurobiological basis of cognitive improvement with rTMS remains unclear, additional studies including genetics, experimental neurophysiology and functional brain imaging are necessary to explore stimulation-related functional changes in the brain.  The authors noted that "[a]ll in all, investigations have to prove the efficacy of rTMS in randomized sham-controlled trials with higher statistical power using larger sample sizes and improved methodology".

In a randomized, double-blind, sham-controlled study, Benninger and colleagues (2011) examined the safety and effectiveness of intermittent theta-burst stimulation (iTBS) in the treatment of motor symptoms in Parkinson disease (PD); iTBS of the motor and DLPFC was investigated in 8 sessions over 2 weeks.  Assessment of safety and clinical efficacy over a 1-month period included timed tests of gait and bradykinesia, Unified Parkinson's Disease Rating Scale (UPDRS), and additional clinical, neuropsychological, and neurophysiologic measures.  These researchers investigated 26 patients with mild-to-moderate PD: 13 received iTBS and 13 sham stimulation.  They found beneficial effects of iTBS on mood, but no improvement of gait, bradykinesia, UPDRS, and other measures.  Electroencephalography/electromyography monitoring recorded no pathologic increase of cortical excitability or epileptic activity.  Few reported discomfort or pain and 1 subject experienced tinnitus during real stimulation.  The authors concluded that iTBS of the motor and pre-frontal cortices appears safe and improves mood, but failed to improve motor performance and functional status in PD.

The BlueCross BlueShield Technology Evaluation Center (TEC)'s assessment on TMS for depression (2011) concludes that "[t]he available evidence does not permit conclusions regarding the effect of TMS on health outcomes or compared with alternatives.  Comparison to alternatives using other observational studies may not be valid due to unmeasured differences in severity of depression between studies and other differences in studies".  It also states that "the current body of evidence can not determine in a rigorous way whether TMS would be as effective as a second course of antidepressant therapy.  Other important gaps in current knowledge include whether TMS is effective as an adjunctive treatment to second-line drug therapy, the durability of TMS treatment, and the effectiveness of retreatment".

In a prospective, randomized, sham-controlled, observer-blinded study, Kranz et al (2010) examined the effects of rTMS on benign essential blepharospasm (BEB).  In 12 patients with BEB, these investigators evaluated the effects of a 15-min session of low-frequency (0.2 Hz) rTMS over the anterior cingulate cortex (ACC) with stimulation intensities at 100 % active motor threshold with 3 stimulation coils: (i) a conventional circular coil (C-coil), (ii) a sham coil (S-coil), and (iii) a Hesed coil (H-coil, which allows stimulation of deeper brain regions.  Primary outcome was the clinical effects on BEB (blink rate, number of spasms rated by a blinded physician and patient rating before, immediately after, and 1 hour after stimulation); secondary outcome was the blink reflex recovery curve.  Subjective stimulation comfort was similar for each coil with no stimulation-associated adverse events.  Stimulation with the H- and C-coils resulted in a significant improvement in all 3 outcome measures and was still detectable in physician rating and patient rating 1 hr after stimulation.  S-coil stimulation had no effects.  The active motor threshold was significantly lower for the H-coil compared to the other 2 coils.  The authors concluded that rTMS could be used as a therapeutic tool in BEB.  Moreover, they noted that compared to the well-established and long-lasting effects of botulinum toxin and in view of the time-consuming nature of rTMS and its short-lasting effects, it should not be used in routine clinical setting at this stage.  Furthermore, they stated that further studies will be necessary to show whether repeated stimulation applications result in lasting clinical effects.

Freitas et al (2011) performed a systematic search of all studies using non-invasive stimulation in Alzheimer's disease (AD) and reviewed all 29 identified articles; 24 focused on measures of motor cortical reactivity and (local) plasticity and functional connectivity, with 8 of these studies assessing also effects of pharmacological agents, and 5  studies focused on the enhancement of cognitive function in AD.  Short-latency afferent inhibition (SAI) and resting motor threshold are significantly reduced in AD patients as compared to healthy elders.  Results on other measures of cortical reactivity, (e.g., intra-cortical inhibition [ICI]), are more divergent.  Acetylcholine-esterase inhibitors and dopaminergic drugs may increase SAI and ICI in AD.  Motor cortical plasticity and connectivity are impaired in AD.  Transcranial magnetic stimulation/transcranial direct current stimulation (tDCS) can induce acute and short-duration beneficial effects on cognitive function, but the therapeutic clinical significance in AD is unclear.  Safety of TMS/tDCS is supported by studies to date.  The authors concluded that TMS/tDCS appears safe in AD, but longer-term risks have been insufficiently considered.  They stated that TMS holds promise as a physiologic biomarker in AD to identify therapeutic targets and monitor pharmacologic effects.  In addition, TMS/tDCS may have therapeutic utility in AD, though the evidence is still very preliminary and cautious interpretation is warranted.

Henkin et al (2011) evaluated the effectiveness of rTMS treatment in patients with phantosmia and phantageusia.  A total of 17 patients with symptoms of persistent phantosmia and phantageusia with accompanying loss of smell and taste acuity were studied.  Before and after treatment, patients were monitored by subjective responses and with psychophysical tests of smell function (olfactometry) and taste function (gustometry).  Each patient was treated with rTMS that consisted of 2 sham procedures followed by a real rTMS procedure.  After sham rTMS, no change in measurements of distortions or acuity occurred in any patient; after initial real rTMS, 2 patients received no benefit; but in the other 15, distortions decreased and acuity increased.  Two of these 15 exhibited total inhibition of distortions and return of normal sensory acuity that persisted for over 5 years of follow-up.  In the other 13, inhibition of distortions and improvement in sensory acuity gradually decreased; but repeated rTMS again inhibited their distortions and improved their acuity.  Eighty-eight percent of patients responded to this therapeutic method, although repeated rTMS was necessary to induce these positive changes.  The authors concluded that these results suggested that rTMS is a potential future therapeutic option to treat patients with the relatively common problems of persistent phantosmia and phantageusia with accompanying loss of taste and smell acuity.  Moreover, they stated that additional systematic studies are necessary to confirm these results.

Transcutaneous electrical nerve stimulation (TENS) is the application of an electrical current through electrodes attached to the skin, and is most commonly used for pain relief.  It has also been employed for the treatment of a range of neurological and psychiatric conditions such as alcohol and drug dependence, depression, as well as headaches.  Transcutaneous electrical nerve stimulation is rarely used for the treatment of dementia.  The use of TENS for these indications entails peripherally applied TENS as well as TENS applied to the head, also known as cranial electrical stimulation (CES).  Although several studies suggested that TENS may produce short-lived improvements in some neurological or psychiatric conditions, the limited data from these studies did not allow definite conclusions on the possible benefits of this intervention.

Rose and colleagues (2008) noted that family caregivers of persons with dementia and their care recipients frequently experience sleep and mood disturbances throughout their caregiving and disease trajectories.  Because conventional pharmacological treatments of sleep and mood disturbances pose numerous risks and adverse effects to elderly persons, the investigation of other interventions is warranted.  As older adults use complementary and alternative medicine interventions for the relief of sleep and mood disturbances, CES may be a viable intervention.  These investigators examined the effects of CES on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer's disease (Rose et al, 2009).  A total fo 38 subjects were randomly assigned to receive active CES or sham CES for 4 weeks.  Both intervention groups reported improvement in study measures from baseline scores.  A trend toward statistically significant differences in daily sleep disturbances was found between the groups.  No differences in depressive symptoms and caregiving appraisal were found between the groups.  The authors concluded that these findings did not fully support the efficacy of the short-term use of active CES versus sham CES to improve sleep disturbances, depressive symptoms, or caregiving appraisal.

There are 2 non-invasive methods to stimulate the brain: (i) TMS, and (ii) tDCS.  Compared to the former approach, the latter does not directly lead to neuronal discharges; tDCS only modulates the excitability level of brain tissue.  Furthermore, tDCS can be employed in a dual mode -- increasing excitability on one hemisphere and decreasing excitability on the other hemisphere.

In a randomized, double-blind, sham-controlled study, Benninger and colleagues (2010) examined the effectiveness of tDCS in the treatment of PD.  The effectiveness of anodal tDCS applied to the motor and pre-frontal cortices was investigated in 8 sessions over 2.5 weeks.  Assessment over a 3-month period included timed tests of gait (primary outcome measure) and bradykinesia in the upper extremities, UPDRS, Serial Reaction Time Task, Beck Depression Inventory, Health Survey and self-assessment of mobility.  A total of 25 PD patients were investigated, 13 receiving tDCS and 12 sham stimulation.  Transcranial direct current stimulation improved gait by some measures for a short time and improved bradykinesia in both the on and off states for longer than 3 months.  Changes in UPDRS, reaction time, physical and mental well being, and self-assessed mobility did not differ between the tDCS and sham interventions.  The authors concluded that tDCS of the motor and pre-frontal cortices may have therapeutic potential in PD, but better stimulation parameters need to be established to make the technique clinically viable.

In a randomized, double-blind, sham-controlled, multi-center study with a parallel design, Shirota et al (2013) examined the effectiveness and stimulation frequency dependence of rTMS over the supplementary motor area (SMA) in PD.  A weekly intervention was performed 8 times, and the effects were monitored up to 20 weeks.  By central registration, participants were assigned to 1 of 3 arms of the study: low-frequency (1-Hz) rTMS, high-frequency (10-Hz) rTMS, and realistic sham stimulation.  The primary end point was the score change of the UPDRS part III from the baseline.  Several non-motor symptom scales such as the Hamilton Rating Scale for Depression, apathy score, and non-motor symptoms questionnaire were defined as secondary end points.  Of the 106 patients enrolled, 36 were allocated to 1-Hz rTMS, 34 to 10-Hz rTMS, and 36 to realistic sham stimulation.  Results showed 6.84-point improvement of the UPDRS part III in the 1-Hz group at the last visit of the 20th week.  Sham stimulation and 10-Hz rTMS improved motor symptoms transiently, but their effects disappeared in the observation period.  Changes in non-motor symptoms (NMS) were not clear in any group.  No severe adverse event was reported.  The authors concluded that 1-Hz rTMS over the SMA was effective for motor, but not non-motor, symptoms in PD.  Moreover, they stated that rTMS is a promising add-on therapy for motor symptoms of PD, whereas establishment of an adequate protocol for NMS treatment using rTMS requires further study.  They noted that the present findings warrant a confirmatory clinical trial for SMA rTMS on PD, undertaken on a larger scale.

In a comparative case study, Plow et al (2011) attempted to standardize a protocol for promoting visual rehabilitative outcomes in post-stroke hemianopia by combining occipital cortical tDCS with vision restoration therapy (VRT).  Two patients, both with right hemianopia after occipital stroke damage were included in this study.  Both patients underwent an identical VRT protocol that lasted 3 months (30 mins, twice-daily, 3 days/week).  In patient 1, anodal tDCS was delivered to the occipital cortex during VRT training, whereas in patient 2 sham tDCS with VRT was performed.  The primary outcome, visual field border, was defined objectively by using high-resolution perimetry.  Secondary outcomes included subjective characterization of visual deficit and functional surveys that assessed performance on activities of daily living.  For patient 1, the neural correlates of visual recovery were also investigated, by using functional magnetic resonance imaging.  Delivery of combined tDCS with VRT was feasible and safe.  High-resolution perimetry revealed a greater shift in visual field border for patient 1 versus patient 2.  Patient 1 also showed greater recovery of function in activities of daily living.  Contrary to the expectation, patient 2 perceived greater subjective improvement in visual field despite objective high-resolution perimetry results that indicated otherwise.  In patient 1, visual function recovery was associated with functional magnetic resonance imaging activity in surviving peri-lesional and bilateral higher-order visual areas.  The authors concluded that these findings of preliminary case comparisons suggested that occipital cortical tDCS may enhance recovery of visual function associated with concurrent VRT through visual cortical re-organization.  They stated that future studies may benefit from incorporating protocol refinements such as those described here, which include global capture of function, control for potential confounds, and investigation of underlying neural substrates of recovery.

In a review on “Transcranial magnetic stimulation in the management of mood disorders”, Allan et al (2011) presented an up-to-date meta-analysis of TMS in the treatment of depression.  These investigators searched Medline and Embase from 1996 until 2008 for randomized sham-controlled trials, with patients and investigators blinded to treatment, and outcome measured using a version of the Hamilton Depression Rating Scale (or similar).  They identified 1,789 studies; 31 were suitable for inclusion, with a cumulative sample of 815 active and 716 sham TMS courses.  These researchers found a moderately sized effect in favor of TMS [Random Effects Model Hedges' g = 0.64, 95 % CI: 0.50 to 0.79].  The corresponding Pooled Peto Odds Ratio for treatment response (less than or equal to 50 % reduction in depression scores) was 4.1 (95 % CI: 2.9 to 5.9).  There was significant variability between study effect sizes.  Meta-regressions with relevant study variables did not reveal any predictors of treatment efficacy.  A total of 9 studies included follow-up data with an average follow-up time of 4.3 weeks; there was no mean change in depression severity between the end of treatment and follow-up (Hedges' g = -0.02, 95 % CI: -0.22 to +0.18) and no heterogeneity in outcome.  The authors concluded that TMS appears to be an effective treatment; however, at 4 weeks' follow-up after TMS, there had been no further change in depression severity.  Problems with finding a suitably blind and ineffective placebo condition may have confounded the published effect sizes.  If the TMS effect is specific, only further large double-blind RCTs with systematic exploration of treatment and patient parameters will help to define optimum treatment indications and regimen.

Leung et al (2009) performed a meta-analysis on the analgesic effect of rTMS on various neuropathic pain states based on their neuroanatomical hierarchy.  Available RCTs were screened.  Pooled individual data (PID) were coded for age, gender, pain neuroanatomical origins, pain duration, and treatment parameters analyses.  Coded pain neuroanatomical origins consist of peripheral nerve (PN); nerve root (NR); spinal cord (SC); trigeminal nerve or ganglion (TGN); and post-stroke supra-spinal related pain (PSP).  Raw data of 149 patients were extracted from 5 (1 parallel, 4 cross-over) selected (from 235 articles) RCTs.  A significant (p < 0.001) overall analgesic effect (mean percent difference in pain visual analog scale (VAS) score reduction with 95 % CI) was detected with greater reduction in VAS with rTMS in comparison to sham.  Including the parallel study (Khedr et al), the TGN subgroup was found to have the greatest analgesic effect (28.8 %), followed by PSP (16.7 %), SC (14.7 %), NR (10.0 %), and PN (1.5 %).  The results were similar when these researchers excluded the parallel study with the greatest analgesic effect observed in TGN (33.0 %), followed by SC (14.7 %), PSP (10.5 %), NR (10.0 %), and PN (1.5 %).  In addition, multiple (versus single, p = 0.003) sessions and lower (greater than 1 and less than or equal to 10 Hz) treatment frequency range (versus greater than 10 Hz) appears to generate better analgesic outcome.  In short, rTMS appears to be more effective in suppressing centrally than peripherally originated neuropathic pain states.  The authors stated that this was the first PID-based meta-analysis to assess the differential analgesic effect of rTMS on neuropathic pain based on the neuroanatomical origins of the pain pathophysiology and treatment parameters.  The derived information serves as a useful resource in regards to treatment parameters and patient population selection for future rTMS-pain studies.

Plow and associates (2012) stated that chronic neuropathic pain is one of the most prevalent and debilitating disorders.  Conventional medical management, however, remains frustrating for both patients and clinicians owing to poor specificity of pharmacotherapy, delayed onset of analgesia and extensive side effects.  Neuromodulation presents as a promising alternative, or at least an adjunct, as it is more specific in inducing analgesia without associated risks of pharmacotherapy.  These investigators discussed common clinical and investigational methods of neuromodulation.  Compared to clinical spinal cord stimulation, investigational techniques of cerebral neuromodulation, both invasive (DBS and motor cortical stimulation [MCS]) and non-invasive (rTMS and tDCS), may be more advantageous.  By adaptively targeting the multi-dimensional experience of pain, subtended by integrative pain circuitry in the brain, including somatosensory and thalamo-cortical, limbic and cognitive, cerebral methods may modulate the sensory-discriminative, affective-emotional and evaluative-cognitive spheres of the pain neuromatrix.  Despite promise, the current state of results alludes to the possibility that cerebral neuromodulation has thus far not been effective in producing analgesia as intended in patients with chronic pain disorders.  These techniques, thus, remain investigational and off-label.  These investigators discussed issues implicated in inadequate efficacy, variability of responsiveness, and poor retention of benefit, while recommending design and conceptual refinements for future trials of cerebral neuromodulation in management of chronic neuropathic pain.

Awad et al (2013) reviewed the basic principles and techniques of TMS and provided information and evidence regarding its applications in spinal cord injury (SCI) clinical rehabilitation.  A review of the available current and historical literature regarding TMS was conducted, and a discussion of its potential use in SCI rehabilitation is presented.  Transcranial magnetic stimulation provides reliable information about the functional integrity and conduction properties of the cortico-spinal tracts and motor control in the diagnostic and prognostic assessment of various neurological disorders.  It allows one to follow the evolution of motor control and to evaluate the effects of different therapeutic procedures.  Motor-evoked potentials can be useful in follow-up evaluation of motor function during treatment and rehabilitation, specifically in patients with SCI and stroke.  Although studies regarding somato-motor functional recovery after SCI have shown promise, more trials are needed to provide strong and substantial evidence.  The authors concluded that TMS is a promising non-invasive tool for the treatment of spasticity, neuropathic pain, and somato-motor deficit after SCI.  They stated that further investigation is needed to demonstrate whether different protocols and applications of stimulation, as well as alternative cortical sites of stimulation, may induce more pronounced and beneficial clinical effects.

Schneider et al (2010) stated that dystonia is associated with impaired somatosensory ability.  The electrophysiological method of rTMS can be used for non-invasive stimulation of the human cortex and can alter cortical excitability and associated behavior.  Among others, rTMS can alter/improve somatosensory discriminatory abilities, as shown in healthy controls.  These researchers applied 5Hz-rTMS over the left primary somatosensory cortex (S1) in 5 patients with right-sided writer's dystonia and 5 controls.  They studied rTMS effects on tactile discrimination accuracy and concomitant rTMS-induced changes in hemodynamic activity measured by functional magnetic resonance imaging (fMRI).  Before rTMS, patients performed worse on the discrimination task than controls even though fMRI showed greater task-related activation bilaterally in the basal ganglia (BG).  In controls, rTMS led to improved discrimination; fMRI revealed this was associated with increased activity of the stimulated S1, bilateral premotor cortex and BG.  In dystonia patients, rTMS had no effect on discrimination; fMRI showed similar cortical effects to controls except for no effects in BG.  Improved discrimination after rTMS in controls is linked to enhanced activation of S1 and BG.  Failure of rTMS to increase BG activation in dystonia may be associated with the lack of effect on sensory discrimination in this group and may reflect impaired processing in BG-S1 connections.  Alternatively, the increased BG activation seen in the baseline state without rTMS may reflect a compensatory strategy that saturates a BG contribution to this task.

Szaflarsk et al (2011) stated that aphasia affects 1/3 of stroke patients with improvements noted only in some of them.  The goal of this exploratory study was to provide preliminary evidence regarding safety and effectiveness of fMRI-guided excitatory rTMS applied to the residual left-hemispheric Broca's area for chronic aphasia treatment.  These researchers enrolled 8 patients with moderate or severe aphasia of more than 1 year after left middle cerebral artery stroke.  Linguistic battery was administered pre-/post-rTMS; a semantic decision/tone decision (SDTD) fMRI task was used to localize left-hemispheric Broca's area.  Repetitive TMS protocol consisted of 10 daily treatments of 200 seconds each using an excitatory stimulation protocol called intermittent theta burst stimulation (iTBS).  Coil placement was targeted individually to the left Broca's.  A total of 6 patients showed significant pre-/post-rTMS improvements in semantic fluency (p = 0.028); they were able to generate more appropriate words when prompted with a semantic category.  Pre-/post-rTMS fMRI maps showed increases in left fronto-temporo-parietal language networks with a significant left-hemispheric shift in the left frontal (p = 0.025), left temporo-parietal (p = 0.038) regions and global language LI (p = 0.018).  Patients tended to report subjective improvement on Communicative Activities Log (mini-CAL; p = 0.075).  None of the subjects reported ill effects of rTMS.  The authors concluded that fMRI-guided, excitatory rTMS applied to the affected Broca's area improved language skills in patients with chronic post-stroke aphasia; these improvements correlated with increased language lateralization to the left hemisphere.  They stated that this rTMS protocol appears to be safe and should be further tested in blinded studies assessing its short- and long-term safety/effectiveness for post-stroke aphasia rehabilitation.

Kakuda et al (2012a) stated that both low-frequency rTMS (LF-rTMS) and intensive occupational therapy (OT) have been recently reported to be clinically beneficial for post-stroke patients with upper limb hemiparesis.  Based on these reports, these researchers developed an inpatient combination protocol of these 2 modalities for the treatment of such patients.  In a pilot study, these investigators examined the safety and feasibility of the protocol in a large number of patients from different institutions, and identified predictors of the clinical response to the treatment.  The study subjects were 204 post-stroke patients with upper limb hemiparesis (mean age at admission of 58.5 +/- 13.4 years, mean time after stroke of 5.0 +/- 4.5 years, +/- SD) from 5 institutions in Japan.  During 15-day hospitalization, each patient received 22 treatment sessions of 20-min LF-rTMS and 120-min intensive OT daily.  Low-frequency rTMS of 1 Hz was applied to the contralesional hemisphere over the primary motor area.  The intensive OT, consisting of 60-min 1-on-1 training and 60-min self-exercise, was provided after the application of LF-rTMS.  Fugl-Meyer Assessment (FMA) and Wolf Motor Function Test (WMFT) were performed serially.  The physiatrists and occupational therapists involved in this study received training prior to the study to standardize the therapeutic protocol.  All patients completed the protocol without any adverse effects.  The FMA score increased and WMFT log performance time decreased significantly at discharge, relative to the respective values at admission (change in FMA score: median at admission, 47 points; median at discharge, 51 points; p < 0.001. change in WMFT log performance time: median at admission, 3.23; median at discharge, 2.51; p < 0.001).  These changes were persistently seen up to 4 weeks after discharge in 79 patients.  Linear regression analysis found no significant relationship between baseline parameters and indexes of improvement in motor function.  The authors concluded that the 15-day inpatient rTMS plus OT protocol is a safe, feasible, and clinically useful neuro-rehabilitative intervention for post-stroke patients with upper limb hemiparesis.  The response to the treatment was not influenced by age or time after stroke onset.  They stated that the effectiveness of the intervention should be confirmed in a randomized controlled study including a control group.

Kakuda et al (2012b) noted that for spastic upper limb hemiparesis after stroke, they developed triple-element protocol of botulinum toxin type A (BoNTA) injection, LF-rTMS, and intensive OT.  These researchers investigated the safety and feasibility of the protocol.   A total of 14 post-stroke patients with spastic upper limb hemiparesis (mean age of 54.9 +/- 9.2 years, time after onset: 87.1 +/- 48.2 months, +/- SD) were included in this study.  In all patients, BoNTA was injected into spastic muscles of the affected upper limb (maximum total dose: 240 units).  Four weeks later, they were hospitalized to receive 22 sessions of 20-min LF-rTMS and 120-min intensive OT daily over 15 days.  Motor function of the affected upper limb was evaluated mainly using FMA, WMFT, motor activity log (MAL), and the severity of spasticity was measured with modified Ashworth scale (MAS) at BoNTA injection, discharge and 4 weeks post-discharge.  All patients completed the protocol without any adverse effects.  The FMA score and MAL scores, but not WMFT performance time, improved significantly at discharge.  The MAS score of all examined muscles decreased significantly between BoNTA and discharge.  The beneficial effect of the protocol on motor function and spasticity was almost maintained until 4 weeks after discharge.  The authors concluded that the protocol is safe and feasible, although further larger studies are needed to confirm its effectiveness.

Ayache et al (2012) stated that non-invasive cortical stimulation (NICS) has been used during the acute, post-acute and chronic post-stroke phases to improve motor recovery in stroke patients having upper- and/or lower-limb paresis.  These investigators reviewed the rationale for using the different NICS modalities to promote motor stroke rehabilitation.  A number of open and placebo-controlled trials have investigated the clinical effect of rTMS or tDCS of the primary motor cortex in patients with motor stroke.  These studies attempted to improve motor performance by increasing cortical excitability in the stroke-affected hemisphere (via HF- rTMS or anodal tDCS) or by decreasing cortical excitability in the contralateral hemisphere (via LF- rTMS or cathodal tDCS).  The goal of these studies was to reduce the inhibition exerted by the unaffected hemisphere on the affected hemisphere and to then restore a normal balance of inter-hemispheric inhibition.  All these NICS techniques administered alone or in combination with various methods of neuro-rehabilitation were found to be safe and equally effective at the short-term on various aspects of post-stroke motor abilities.  However, they stated that the long-term effect of NICS on motor stroke needs to be further evaluated before considering the use of such a technique in the daily routine management of stroke.

Corti et al (2012) stated that rTMS is known to modulate cortical excitability and has thus been suggested to be a therapeutic approach for improving the efficacy of rehabilitation for motor recovery after stroke.  In addition to producing effects on cortical excitability, stroke may affect the balance of trans-callosal inhibitory pathways between motor primary areas in both hemispheres: the affected hemisphere (AH) may be disrupted not only by the infarct itself but also by the resulting asymmetric inhibition from the unaffected hemisphere, further reducing the excitability of the AH.  Conceptually, therefore, rTMS could be used therapeutically to restore the balance of inter-hemispheric inhibition after stroke.  Repetitive TMS has been used in 2 ways: LF stimulation (less than or equal to 1 Hz) to the motor cortex of the unaffected hemisphere to reduce the excitability of the contralesional hemisphere or HF stimulation (greater than 1 Hz) to the motor cortex of the AH to increase excitability of the ipsilesional hemisphere.  These researchers collated evidence regarding the safety and efficacy of HF- rTMS to the motor cortex of the AH.  The studies included investigated the concurrent effects of rTMS on the excitability of cortico-spinal pathways and upper-limb motor function in adults after stroke.  The findings of this review suggested that rTMS applied to the AH is a safe technique and could be considered an effective approach for modulating brain function and contributing to motor recovery after stroke.  The authors concluded that although the studies included in this review provided important information, double-blinded, sham-controlled phase II and phase III clinical trials with larger sample sizes are needed to validate this novel therapeutic approach.

In an evidence-based review, Wong and Tsang (2013) reported an updated evaluation and critical appraisal of available studies that investigated the effectiveness of rTMS on post-stroke aphasia rehabilitation.  A literature search was performed to identify studies that investigated the therapeutic effects of rTMS on post-stroke aphasia in various electronic databases, from their inception to 2011.  The selected studies were classified according to the types of participants, types of interventions, outcome measures, and results.  The methodological qualities of the selected studies were evaluated using the Physiotherapy Evidence Database scale.  The current review was based on 12 studies, including open-label designs and controlled trials, which showed a positive effect of rTMS, with or without conventional rehabilitation, on post-stroke aphasia compared with sham or conventional rehabilitation alone.  About 41 % of the selected studies reported the long-term effect of rTMS on aphasia recovery.  No adverse effect was reported.  The authors concluded that the current review revealed that rTMS with or without conventional rehabilitation has positive effects on post-stroke aphasia.  The studies also contributed to the plausible mechanisms of stroke recovery.  However, they stated that with the concerns over the methodology of the selected studies in this review, a larger-scale, multi-center, well-designed RCT involving different phases and types of aphasia needs to be carried out before recommending rTMS as a complementary treatment for post-stroke aphasia.

In a systematic review, Peng et al (2012) evaluated the effectiveness of rTMS for the treatment of chronic tinnitus.  Data Sources Relevant electronic databases and a reference list of articles published up to January 2012 were searched.  Randomized controlled clinical trials of all types of rTMS treatment for patients with chronic tinnitus were included.  A total of 5 trials (160 participants) were included in this review.  Repetitive TMS showed benefits in the short-term, but the long-term effects are questionable.  The Tinnitus Handicap Inventory (THI) and the visual analog scale (VAS) were the major assessment methods used.  After active TMS stimulation, the reduction in the THI total score and VAS was significant compared with baseline at the first time-point assessed and in the short-term (2 weeks and 4 weeks).  The longest follow-up time was 26 weeks after treatment, and the shortest follow-up time was 2 weeks.  No severe side effects were reported from the use of rTMS.  Differences in age, hearing level, duration of tinnitus of the included patients, and the condition of sham treatment may influence the effect.  The authors concluded that rTMS could be a new therapeutic tool for the treatment of chronic tinnitus, and thus far they have not been able to demonstrate any substantial risk from rTMS treatment.  However, they stated that the long-term effects of rTMS treatment for tinnitus are not clear and will require further study.

Plewnia et al (2012) examined if 4 weeks of bilateral rTMS to the temporal or temporo-parietal cortex is effective and safe in the treatment of chronic tinnitus.  In this controlled 3-armed trial, 48 patients with chronic tinnitus were treated with 4 weeks (20 sessions) of bilateral continuous theta burst stimulation (cTBS).  They were randomized to stimulation above the temporal cortex, the temporo-parietal cortex, or as sham condition behind the mastoid.  Patients were masked for the stimulation condition.  Tinnitus severity was assessed after 2 and primarily 4 weeks of treatment and at 3 months follow-up with the tinnitus questionnaire and by a tinnitus change score.  Audiologic safety was monitored by pure-tone and speech audiometry after 2 and 4 weeks of cTBS.  Tinnitus severity was slightly reduced from baseline by a mean (SD) 2.6 (8.2) after sham, 2.4 (8.0) after temporo-parietal, 2.2 (8.3) after temporal treatment of 16 patients each, but there was no significant difference between sham treatments and temporal (CI: -5.4 to +6.7) or temporo-parietal cTBS (CI: -5.9 to +6.3) or real cTBS (CI: -7 to +5.1).  Patients' global evaluation of tinnitus change after treatment did not indicate any effects.  Audiologic measures were unaffected by treatment.  The authors concluded that treating chronic tinnitus for 4 weeks by applying cTBS to the temporal or temporo-parietal cortex of both hemispheres appears to be safe but not more effective than sham stimulation.  However, these results are not to be generalized to all forms of rTMS treatments for tinnitus.

In an editorial that accompanied the afore-mentioned study, Triggs and Hajioff (2012) stated that “At present, rTMS should be classified as “U” by the American Academy of Neurology classification of recommendation: the data are inadequate and conflicting, and the treatment is unproven”.

Slotema et al (2012) provided an update of the literature on the efficacy of rTMS for auditory verbal hallucinations (AVH) and investigated the effect of rTMS 1 month after the end of treatment.  A literature search was performed from 1966 through August 2012 using Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Embase Psychiatry, Ovid Medline, PsycINFO and PubMed.  Randomized, double-blind, sham-controlled studies with severity of AVH or severity of psychosis as an outcome measure were included.  Data were obtained from 17 randomized studies of rTMS for AVH; 5 studies fulfilled the criteria for the meta-analysis on the effect of rTMS 1 month after the end of treatment.  Standardized mean weighted effect sizes of rTMS versus sham were computed on pre- and post-treatment comparisons.  The mean weighted effect size of rTMS directed at the left temporo-parietal area was 0.44 (95 % CI: 0.19 to 0.68).  A separate meta-analysis including studies directing rTMS at other brain regions revealed a mean weighted effect size of 0.33 (95 % CI: 0.17 to 0.50) in favor of real TMS.  The effect of rTMS was no longer significant at 1 month of follow-up (mean weighted effect size = 0.40, 95 % CI: -0.23 to 0.102).  Side effects were mild and the number of dropouts in the real TMS group was not significantly higher than in the sham group.  The authors concluded that with the inclusion of studies with larger patient samples, the mean weighted effect size of rTMS directed at the left temporo-parietal area for AVH has decreased, although the effect is still significant.  The duration of the effect of rTMS may be less than 1 month.  Moreover, they stated that more research is needed in order to optimize parameters and further evaluate the clinical relevance of this intervention.

In a meta-analysis, Hsu et al (2012) investigated the effects of rTMS on upper limb motor function in patients with stroke.  These investigators searched for RCTs published between January 1990 and October 2011 in PubMed, Medline, Cochrane, and CINAHL using the following key words: stroke, cerebrovascular accident, and repetitive transcranial magnetic stimulation.  The mean effect size and a 95 % CI were estimated for the motor outcome and motor threshold using fixed and random effect models.  Eighteen of the 34 candidate articles were included in this analysis.  The selected studies involved a total of 392 patients.  A significant effect size of 0.55 was found for motor outcome (95 % CI: 0.37 to 0.72).  Further sub-group analyses demonstrated more prominent effects for subcortical stroke (mean effect size, 0.73; 95 % CI: 0.44 to 1.02) or studies applying low-frequency rTMS (mean effect size, 0.69; 95 % CI: 0.42 to 0.95).  Only 4 patients of the 18 articles included in this analysis reported adverse effects from rTMS.  The authors concluded that rTMS has a positive effect on motor recovery in patients with stroke, especially for those with subcortical stroke.  Low-frequency rTMS over the unaffected hemisphere may be more beneficial than high-frequency rTMS over the affected hemisphere.  Recent limited data suggested that intermittent theta-burst stimulation over the affected hemisphere might be a useful intervention.  They stated that further well-designed studies in a larger population are needed to better elucidate the differential roles of various rTMS protocols in stroke treatment.

Demirtas-Tatlidede et al (2012) reviewed novel techniques of non-invasive brain stimulation (NBS), which may have value in assessment and treatment of traumatic brain injury (TBI).  Review of the following techniques: TMS, transcranial DCS (tDCS), low-level laser therapy, and transcranial Doppler sonography.  Furthermore, these investigators provided a brief overview of TMS studies to date.  They described the rationale for the use of these techniques in TBI, discussed their possible mechanisms of action, and raised a number of considerations relevant to translation of these methods to clinical use.  Depending on the stimulation parameters, NBS may enable suppression of the acute glutamatergic hyper-excitability following TBI and/or counter the excessive GABAergic effects in the sub-acute stage.  In the chronic stage, brain stimulation coupled to rehabilitation may enhance behavioral recovery, learning of new skills, and cortical plasticity.  Correlative animal models and comprehensive safety trials seem critical to establish the use of these modalities in TBI.  The authors concluded that different forms of NBS techniques harbor the promise of diagnostic and therapeutic utility, particularly to guide processes of cortical re-organization and enable functional restoration in TBI.  They noted that future lines of safety research and well-designed clinical trials in TBI are warranted to determine the capability of NBS to promote recovery and minimize disability.

In a randomized, controlled pilot study, Short et al (2011) examined the effects of adjunctive left pre-frontal rTMS on patients with fibromyalgia pain.  A total of 20 patients with fibromyalgia, defined by American College of Rheumatology criteria, and were randomized to receive 4,000 pulses at 10 Hz TMS (n = 10), or sham TMS (n = 10) treatment for 10 sessions over 2 weeks along with their standard medications, which were fixed and stable for at least 4 weeks before starting sessions.  Subjects recorded daily pain, mood, and activity.  Blinded raters assessed pain, mood, functional status, and tender points weekly with the Brief Pain Inventory, Hamilton Depression Rating Scale, and Fibromyalgia Impact Questionnaire.  No statistically significant differences between groups were observed.  Patients who received active TMS had a mean 29 % (statistically significant) reduction in pain symptoms in comparison to their baseline pain.  Sham-TMS participants had a 4 % non-significant change in daily pain from their baseline pain.  At 2 weeks after treatment, there was a significant improvement in depression symptoms in the active group compared to baseline.  Pain reduction preceded anti-depressant effects.  TMS was well-tolerated, with few side effects.  The authors concluded that further studies that address study limitations (small sample size and short follow-up) are needed to determine whether daily prefrontal TMS may be an effective, durable, and clinically useful treatment for fibromyalgia symptoms.

Marlow et al (2013) systematically reviewed the literature to date applying rTMS or tDCS for patients with fibromyalgia syndrome (FMS).  Electronic bibliography databases screened included PubMed, Ovid MEDLINE, PsychINFO, CINAHL, and Cochrane Library.  The keyword "fibromyalgia" was combined with ("transcranial" and "stimulation") or "TMS" or "tDCS" or "transcranial magnetic stimulation" or "transcranial direct current stimulation".  Nine of 23 studies were included; brain stimulation sites comprised either the primary motor cortex (M1) or the dorso-lateral pre-frontal cortex (DLPFC).  Five studies used rTMS (high-frequency-M1: 2, low-frequency-DLPFC: 2, high-frequency-DLPFC: 1), while 4 applied tDCS (anodal-M1: 1, anodal-M1/DLPFC: 3); 8 were double-blinded RCTS.  Most (80 %) rTMS studies that measured pain reported significant decreases, while all (100 %) tDCS studies with pain measures reported significant decreases.  Greater longevity of significant pain reductions was observed for excitatory M1 rTMS/tDCS.  The authors concluded that studies involving excitatory rTMS/tDCS at M1 showed analogous pain reductions as well as considerably fewer side effects compared to FDA-approved FMS pharmaceuticals.  The most commonly reported side effects were mild, including transient headaches and scalp discomforts at the stimulation site.  Yearly use of rTMS/tDCS regimens appears costly ($11,740 to 14,507/year); however, analyses to appropriately weigh these costs against clinical and quality of life benefits for patients with FMS are lacking.  Consequently, rTMS/tDCS should be considered when treating patients with FMS, particularly those who are unable to find adequate symptom relief with other therapies.  Moreover, they stated that further work into optimal stimulation parameters and standardized outcome measures is needed to clarify associated efficacy and effectiveness.

Navigated Transcranial Magnetic Stimulation:

Navigated TMS is being studied as a diagnostic tool to stimulate functional cortical areas at precise anatomical locations to induce measurable responses.  This technology is being investigated to map functionally essential motor areas for diagnostic purposes and for treatment planning. 

Navigated TMS is a novel tool for pre-operative functional mapping.  It has been used for motor mapping in the vicinity of rolandic brain lesions as well as for mapping human language areas.

Picht et al (2011) compared the accuracy of a 3-dimensional MRI-navigated TMS system with the gold standard of direct cortical stimulation.  The primary motor areas of 20 patients with rolandic tumors were mapped pre-operatively with navigated TMS at 110 % of the individual resting motor threshold.  Intra-operative direct cortical stimulation was available from 17 patients.  The stimulus locations eliciting the largest electromyographic response in the target muscles ("hotspots") were determined for both methods.  The navigated TMS and direct cortical stimulation hotspots were located on the same gyrus in all cases.  The mean +/- SEM distance between the navigated TMS and direct cortical stimulation hotspots was 7.83 +/- 1.18 mm for the abductor pollicis brevis (APB) muscle (n = 15) and 7.07 +/- 0.88 mm for the tibialis anterior (TA) muscle (n = 8).  When a low number of direct cortical stimulations was performed, the distance between the navigated TMS and direct cortical stimulation hotspots increased substantially (r = -0.86 for APB).  After exclusion of the cases with less than 15 direct cortical stimulation APB responses, the mean +/- SEM distance between the hotspots was only 4.70 +/- 1.09 mm for APB (n = 8).  The authors concluded that peri-tumoral mapping of the motor cortex by navigated TMS agreed well with the gold standard of direct cortical stimulation.  Thus, navigated TMS is a reliable tool for pre-operative mapping of motor function.  These preliminary findings need to be validated by well-designed studies with larger number of participants.

Picht et al (2012) evaluated how much influence, benefit, and impact navigated TMS has on the surgical planning for tumors near the motor cortex.  This study reviewed the records of 73 patients with brain tumors in or near the motor cortex, mapped pre-operatively with navigated TMS.  The surgical team prospectively classified how much influence the navigated TMS results had on the surgical planning.  Step-wise regression analysis was used to explore which factors predict the amount of influence, benefit, and impact navigated TMS has on the surgical planning.  The influence of navigated TMS on the surgical planning was as follows: it confirmed the expected anatomy in 22 % of patients, added knowledge that was not used in 23 %, added awareness of high-risk areas in 27 %, modified the approach in 16 %, changed the planned extent of resection in 8 %, and changed the surgical indication in 3 %.  The authors concluded that navigated TMS had an objective benefit on the surgical planning in 25 % of the patients and a subjective benefit in an additional 50 % of the patients.  It had an impact on the surgery itself in just more than 50 % of the patients.

Krieg et al (2012) stated that navigated TMS is a newly evolving technique.  Despite its supposed purpose (e.g., pre-operative central region mapping), little is known about its accuracy compared with established modalities like direct cortical stimulation and functional MR imaging (fMRI).  These researchers compared the accuracy of navigated TMS with direct cortical stimulation and fMRI.  Fourteen patients with tumors in or close to the pre-central gyrus were examined using navigated TMS for motor cortex mapping, as were 12 patients with lesions in the subcortical white matter motor tract.  Moreover, pre-operative fMRI and intra-operative mapping of the motor cortex were performed via direct cortical stimulation, and the outlining of the motor cortex was compared.  In the 14 cases of lesions affecting the pre-central gyrus, the primary motor cortex as outlined by navigated TMS correlated well with that delineated by intra-operative direct cortical stimulation mapping, with a deviation of 4.4 +/- 3.4 mm between the 2 methods.  In comparing navigated TMS with fMRI, the deviation between the 2 methods was much larger: 9.8 +/- 8.5 mm for the upper extremity and 14.7 +/- 12.4 mm for the lower extremity.  In 13 of 14 cases, the surgeon admitted easier identification of the central region because of navigated TMS.  The procedure had a subjectively positive influence on the operative results in 5 cases and was responsible for a changed resection strategy in 2 cases.  One of 26 patients experienced navigated TMS as unpleasant; none found it painful.  The authors concluded that navigated TMS correlates well with direct cortical stimulation as a gold standard despite factors that are supposed to contribute to the inaccuracy of navigated TMS.  Moreover, surgeons have found navigated TMS to be an additional and helpful modality during the resection of tumors affecting eloquent motor areas, as well as during pre-operative planning.  These findings need to be confirmed.

Frey et al (2012) established a novel approach for fiber tracking based on navigated TMS mapping of the primary motor cortex and proposed a new algorithm for determination of an individualized fractional anisotropy value for reliable and objective fiber tracking.  A total of 50 patients (22 females, 28 males; median age of 58 years, range of 20 to 80) with brain tumors compromising the primary motor cortex and the cortico-spinal tract underwent pre-operative MRI and navigated TMS mapping.  Stimulation spots evoking muscle potentials (MEP) closest to the tumor were imported into the fiber tracking software and set as seed points for tractography.  Next the individual FA threshold, namely, the highest FA value leading to visualization of tracts at a pre-defined minimum fiber length of 110 mm, was determined.  Fiber tracking was then performed at a fractional anisotropy value of 75 % and 50 % of the individual FA threshold.  In addition, fiber tracking according to the conventional knowledge-based approach was performed.  Results of tractography of either method were presented to the surgeon for pre-operative planning and integrated into the navigation system and its impact was rated using a questionnaire.  Mapping of the motor cortex was successful in all patients.  A fractional anisotropy threshold for cortico-spinal tract reconstruction could be obtained in every case.  TMS-based results changed or modified surgical strategy in 23 of 50 patients (46 %), whereas knowledge-based results would have changed surgical strategy in 11 of 50 patients (22 %).  Tractography results facilitated intra-operative orientation and electrical stimulation in 28 of 50 (56 %) patients.  Tracking at 75 % of the individual FA thresholds was considered most beneficial by the respective surgeons.  The authors concluded that fiber tracking based on navigated TMS by the proposed standardized algorithm represents an objective visualization method based on functional data and provides a valuable instrument for pre-operative planning and intra-operative orientation and monitoring.  This was a small study and it did not validate navigated TMS findings with improved health outcomes.

Tarapore et al (2012) noted that direct cortical stimulation is the gold-standard technique for motor mapping during craniotomy.  However, pre-operative non-invasive motor mapping is becoming increasingly accurate.  Two such non-invasive modalities are navigated TMS and magnetoencephalography (MEG) imaging.  These investigators compared the accuracy of TMS to both direct cortical stimulation and MEG imaging.  Patients with tumors in proximity to primary motor cortex underwent pre-operative TMS and MEG imaging for motor mapping.  The patients subsequently underwent motor mapping via intra-operative direct cortical stimulation.  The loci of maximal response were recorded from each modality and compared.  Motor strength was assessed at 3 months post-operatively.  Transcranial magnetic stimulation and MEG imaging were performed on 24 patients.  Intra-operative direct cortical stimulation yielded 8 positive motor sites in 5 patients.  The median distance +/- SEM between TMS and direct cortical stimulation motor sites was 2.13 +/- 0.29 mm, and between TMS and MEG imaging motor sites was 4.71 +/- 1.08 mm.  In no patients did direct cortical stimulation motor mapping reveal a motor site that was unrecognized by TMS.  Three of 24 patients developed new, early neurological deficit in the form of upper-extremity paresis.  At the 3-month follow-up evaluation, 2 of these patients were significantly improved, experiencing difficulty only with fine motor tasks; the remaining patient had improvement to 4/5 strength.  There were no deaths over the course of the study.  The authors concluded that maps of the motor system generated with TMS correlate well with those generated by both MEG imaging and direct cortical stimulation.  Negative TMS mapping also correlates with negative direct cortical stimulation mapping. 

In a feasibility study, Forster et al (2012) examined cortical motor representation after resection of peri-rolandic World Health Organization grade II and III gliomas using navigated TMS.  A total of 5 patients were examined before neurosurgery and after a follow-up period of 17.7 +/- 6.8 months.  As a control, 5 healthy age-matched subjects were equally studied by navigated TMS in 2 sessions spaced 12.6 (range of 2 to 35) days apart.  Resting motor thresholds (RMT), hotspots and centers of gravity (CoG) were identified for the first dorsal interosseous (FDI), APB, extensor digitorum (EXT), TA and abductor hallucis (AH) muscles.  Euclidian distances, coefficients of variance and intra-class correlation coefficients (ICC) were calculated.  Healthy subjects showed moderate-to-excellent reliability measurement of RMT (ICC = 0.69 to 0.94).  Average displacement of CoGs across sessions was 0.68 +/- 0.34 cm in the dominant and 0.76 +/- 0.38 cm in the non-dominant hemisphere; hotspots moved 0.87 +/- 0.51 cm and 0.83 +/- 0.45 cm, respectively.  In 1 patient these parameters differed significantly from the control group (p < 0.05 for both CoGs and hotspots).  Overall, all patients' CoGs moved 1.12 +/- 0.93 cm, and hotspots were 1.06 +/- 0.7 cm apart.  In both patients and healthy subjects, movement of assessed parameters was more important along the X- than the Y-axis.  The authors concluded that navigated TMS allows evaluating cortical re-organization after brain tumor surgery.  It may contribute to the understanding of neurofunctional dynamics, thus influencing therapeutic strategy.

Makela et al (2012) stated that navigated TMS has been suggested to be useful in pre-operative functional localization of motor cortex in patients having tumors close to the somato-motor cortex.  These researchers described functional plasticity of motor cortex indicated by navigated TMS in 2 patients with epilepsy.  Navigated TMS, fMRI, diffusion-tensor (DT)-tractography and MEG were utilized to pre-operatively localize motor cortical areas in the work-up for epilepsy surgery.  The localizations were compared with each other, with the cortical anatomical landmarks, and in 1 patient with invasive electrical cortical stimulation (ECS).  In 2 out of 19 studied patients, navigated TMS identified motor cortical sites that differed from those indicated by anatomical landmarks.  In 1 patient, navigated TMS activated preferentially premotor cortex rather than pathways originating from the pre-central gyrus.  Functional MRI and MEG localizations conformed with navigated TMS whereas ECS localized finger motor function into the pre-central gyrus.  Resection of the area producing motor responses in biphasic navigated TMS did not produce a motor deficit.  In the other patient, navigated TMS indicated abnormal ipsilateral hand motor cortex localization and confirmed the functionality of aberrant motor cortical representations of the left foot also indicated by fMRI and DT-tractography.  The authors concluded that navigated TMS may reveal the functional plasticity and shifts of motor cortical function.  Epileptic foci may modify cortical inhibition and the navigated TMS results.  Thus, the authors noted that in some patients with epilepsy, the navigated TMS results need to be interpreted with caution with regard to surgical planning.

In summary, there is insufficient evidence from peer-reviewed medical literature that navigated TMS is an effective clinical diagnostic test.  Most published studies entailed small number of subjects; well-designed studies with larger sample sizes are needed to ascertain how this test can reduce clinical diagnostic uncertainty or impact treatment planning.

 
CPT Codes / HCPCS Codes / ICD-9 Codes
Transcranial/navigated transcranial Magnetic Stimulation:
CPT codes not covered for indications listed in the CPB:
0310T
90867
90868
90869
HCPCS codes not covered for indications listed in the CPB:
G0295 Electromagnetic therapy, to one or more areas
ICD-9 codes not covered for indications listed in the CPB (not all-inclusive):
191.0 - 191.9 Malignant neoplasm of brain
225.0 Benign neoplasm of brain
290.0 - 319 Mental disorders
307.51 Bulimia nervosa
331.0 Alzheimer’s disease
332.0 - 332.1 Parkinson's Disease
333.81 Blepharospasm
333.83 Spasmodic torticollis
334.1 Hereditary spastic paraplegia
335.20 Amyotrophic lateral sclerosis
339.00 - 339.89 Other headache syndromes
342.10 - 342.12 Spastic hemiplegia
345.00 – 345.91 Epilepsy and recurrent seizures
346.00 - 346.93 Migraine
388.30 - 388.32 Tinnitus
438.11 Late effects of cerebrovascular disease, aphasia
438.20 – 438.22 Late effects of cerebrovascular disease, hemiplegia/hemiparesis
438.82 Other late effect of cerebrovascular disease, dysphagia
478.75 Laryngeal spasm
530.0 Achalasia and cardiospasm
530.5 Dyskinesia of esophagus
537.81 Pylorospasm
564.6 Anal spasm
576.5 Spasm of sphincter of Oddi
728.85 Spasm of muscle
729.1 Myalgia and myositis, unspecified
729.2 Neuralgia, neuritis, and radiculitis, unspecified [neuropathic pain]
780.1 Hallucinations (auditory)
780.50 - 780.59 Sleep disturbances
781.0 Abnormal involuntary movements
781.1 Disturbances of sensation of smell and taste [dysfunction]
781.3 Lack of coordination
784.0 Headache
854.00 – 854.19 Intracranial injury of other and unspecified nature [traumatic brain injury]
Other ICD-9 codes related to the CPB:
E936.4 Adverse effect of anti-parkinsonism drugs
Cranial Electrical Stimulation:
CPT codes not covered for indications listed in the CPB:
64550
HCPCS codes not covered for indications listed in the CPB:
A4556 Electrodes (e.g., apnea monitor), per pair
A4557 Lead wires (e.g., apnea monitor), per pair
A4558 Conductive gel or paste, for use with electrical device (e.g., TENS, NMES), per oz.
A4595 Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES)
E0720 Transcutaneous electrical nerve stimulator (TENS) device, two leads, localized stimulation
E0730 Transcutaneous electrical nerve stimulator (TENS) device, four or more leads, for multiple nerve stimulation
Other HCPCS codes related to the CPB:
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care
ICD-9 codes not covered for indications listed in the CPB (not all-inclusive):
290.0 - 319 Mental disorders
331.0 Alzheimer’s disease
332.0 - 332.1 Parkinson's disease
339.00 - 339.89 Other headache syndromes
346.00 - 346.93 Migraine
438.11 Late effects of cerebrovascular disease, aphasia
438.20 - 438.22 Late effects of cerebrovascular disease, hemiplegia/hemiparesis
729.1 Myalgia and myositis, unspecified
729.2 Neuralgia, neuritis, and radiculitis, unspecified [neuropathic pain]
780.50 - 780.59 Sleep disturbances
784.0 Headache
854.00 - 854.19 Intracranial injury of other and unspecified nature [traumatic brain injury]


The above policy is based on the following references:

Transcranial Magnetic Stimulation:

  1. Klein E, Kreinin I, Chistyakov A, et al. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression. Arch En Psychiatry. 1999;56(4):315-320.
  2. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation. Applications in neuropsychiatry. Arch Gen Psychiatry. 1999;56(4):300-311.
  3. Cracco RQ, Cracco JB, Maccabee PJ, Amassian VE. Cerebral function revealed by transcranial magnetic stimulation. J Neurosci Methods. 1999;86(2):209-219.
  4. Kirkcaldie M, Pridmore S, Reid P. Bridging the skull: Electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) in psychiatry. Convul Ther. 1997;13(2):83-91.
  5. Loo C, Mitchell P, Sachdev P, et al. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry. 1999;156(6):946-948.
  6. Hasey G. Transcranial magnetic stimulation in the treatment of mood disorder: A review and comparison with electroconvulsive therapy. Can J Psychiatry. 2001;46(8):720-727.
  7. McNamara B, Ray JL, Arthurs J, et al. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med. 2001;31(7):1141-1146.
  8. Lisanby SH, Kinnunen LH, Crupain MJ. Applications of TMS to therapy in psychiatry. J Clin Neurophysiol. 2002;19(4):344-360.
  9. Fitzgerald PB, Brown TL, Daskalakis ZJ. The application of transcranial magnetic stimulation in psychiatry and neurosciences research. Acta Psychiatr Scand. 2002;105(5):324-340.
  10. Martin JL, Barbanoj MJ, Schlaepfer TE, et al. Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. Br J Psychiatry. 2003;182:480-491
  11. Padberg F, Moller HJ. Repetitive transcranial magnetic stimulation : Does it have potential in the treatment of depression? CNS Drugs. 2003;17(6):383-403.
  12. Gershon AA, Dannon PN, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry. 2003;160(5):835-845.
  13. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol. 2003;2(3):145-156.
  14. Alberta Heritage Foundation for Medical Research (AHFMR). Repetitive transcranial magnetic stimulation. Tech Brief. Edmonton, AB: AHFMR; 1999.
  15. McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med. 2001;31(7):1141-1146.
  16. Holtzheimer PE, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull. 2001;35(4):149-169.
  17. Dahl Alv A, Aarre Trond F, Johansen Jarle B, et al. Transcranial magnetic stimulation in the treatment of depressions. Oslo, Norway: The Norwegian Centre for Health Technology Assessment (SMM); 2001.
  18. Martin JLR, Barbanoj MJ, Schlaepfer TE, et al. Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev. 2001;(4):CD003493.
  19. Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psych Pract. 2002;8(5):270-275.
  20. Aarre TF, Dahl AA, Johansen JB, et al. Efficacy of repetitive transcranial magnetic stimulation in depression: A review of the evidence. Nordic J Psych. 2003;57(3):227-232.
  21. Martin JLR, Barbanoj MJ, Pérez V, Sacristán M. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev. 2003;(2):CD003387.
  22. Ontario Ministry of Health and Long-Term Care, Medical Advisory Secretariat. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of major depressive disorder. Health Technology Review. Toronto, ON: Ontario Ministry of Health and Long-Term Care; June 2004. Available at: http://www.health.gov.on.ca/english/providers/program/mas/archive.html. Accessed July 20, 2005.
  23. Miniussi C, Bonato C, Bignotti S, et al. Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: An efficacious therapy for major drug-resistant depression? Clin Neurophysiol. 2005;116(5):1062-1071.
  24. Couturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: A systematic review and meta-analysis. J Psychiatry Neurosci. 2005;30(2):83-90.
  25. Hoffman RE, Gueorguieva R, Hawkins KA, et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: Safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry. 2005;58(2):97-104.
  26. Orth M, Kirby R, Richardson MP, et al. Subthreshold rTMS over pre-motor cortex has no effect on tics in patients with Gilles de la Tourette syndrome. Clin Neurophysiol. 2005;116(4):764-768.
  27. Canavero S, Bonicalzi V. Transcranial magnetic stimulation for central pain. Curr Pain Headache Rep. 2005;9(2):87-89.
  28. Pridmore S, Oberoi G, Marcolin M, George M. Transcranial magnetic stimulation and chronic pain: Current status. Australas Psychiatry. 2005;13(3):258-265.
  29. Dell'Osso B, Altamura AC, Allen A, Hollander E. Brain stimulation techniques in the treatment of obsessive-compulsive disorder: Current and future directions. CNS Spectr. 2005;10(12):966-979, 983.
  30. Baghai TC, Moller HJ, Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des. 2006;12(4):503-515.
  31. Fumal A, Coppola G, Bohotin V, et al. Induction of long-lasting changes of visual cortex excitability by five daily sessions of repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers and migraine patients. Cephalalgia. 2006;26(2):143-149.
  32. International Society on Transcranial Stimulation (ISTS). Managing the risks of repetitive transcranial stimulation. Consensus Statement. Bern, Switzerland: ISTS; June 2004. Available at: www.ists.unibe.ch/ . Accessed June 20, 2006.
  33. Wagle-Shukla A, Angel MJ, Zadikoff C, et al. Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. Neurology. 2007;68(9):704-705.
  34. Rossini PM, Rossi S. Transcranial magnetic stimulation: Diagnostic, therapeutic, and research potential. Neurology. 2007;68(7):484-488.
  35. Nemeroff CB. The burden of severe depression: A review of diagnostic challenges and treatment alternatives. J Psychiatr Res. 2007;41(3-4):189-206.
  36. Smith JA, Mennemeier M, Bartel T, et al. Repetitive transcranial magnetic stimulation for tinnitus: A pilot study. Laryngoscope. 2007;117(3):529-534.
  37. Plewnia C, Reimold M, Najib A, et al. Moderate therapeutic efficacy of positron emission tomography-navigated repetitive transcranial magnetic stimulation for chronic tinnitus: A randomised, controlled pilot study. J Neurol Neurosurg Psychiatry. 2007;78(2):152-156.
  38. Prasko J, Zalesky R, Bares M, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: A randomized, double blind sham controlled study. Neuro Endocrinol Lett. 2007;28(1):33-38.
  39. Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry. 2007;164(1):73-81. 
  40. Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC). Rapid transcranial magnetic stimulation for stroke rehabilitation; horizon scanning prioritizing summary - volume 15. Adelaide, SA: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); 2007.
  41. Canadian Agency for Drugs and Technologies in Health (CADTH). Transcranial magnetic stimulation may aid in stroke rehabilitation. Health Technology Update Issue 4. Ottawa, ON: CADTH; September 2006.
  42. McLoughlin DM, Mogg A, Eranti S, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: A multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess. 2007;11(24):1-68.
  43. Medical Services Advisory Committee (MSAC). Repetitive transcranial magnetic stimulation (rTMS). MSAC Application No. 1101. Canberra, ACT: MSAC; 2007.
  44. Centonze D, Koch G, Versace V, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology. 2007;68(13):1045-1050.
  45. Lee SL, Abraham M, Cacace AT, Silver SM. Repetitive transcranial magnetic stimulation in veterans with debilitating tinnitus: A pilot study. Otolaryngol Head Neck Surg. 2008;138(3):398-399.
  46. National Institute for Health and Clinical Excellence. Transcranial magnetic stimulation for severe depression. Interventional Procedure Guidance 242. London, UK: NICE; November 2007.
  47. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216.
  48. Associated Press. Magnet device aims to treat depression patients. Health News. Philadelphia, PA: InteliHealth; October 21, 2008. (Study has been completed. Available at: http://clinicaltrials.gov/ct2/show/NCT00149838. Accessed June 19, 2012).
  49. Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: Clinical response in an open-label extension trial. J Clin Psychiatry. 2008;69(3):441-451.
  50. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: A comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008;69(2):222-232.
  51. Mogg A, Pluck G, Eranti SV, et al. A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. Psychol Med. 2008;38(3):323-333.
  52. Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ, et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: Reproducibility and duration of the antidepressant effect in medication-free patients. J Clin Psychiatry. 2008;69(6):930-934.
  53. André-Obadia N, Mertens P, Gueguen A, et al. Pain relief by rTMS: Differential effect of current flow but no specific action on pain subtypes. Neurology. 2008;71(11):833-840.
  54. Pigot M, Loo C, Sachdev P. Repetitive transcranial magnetic stimulation as treatment for anxiety disorders. Expert Rev Neurother. 2008;8(10):1449-1455.
  55. Walpoth M, Hoertnagl C, Mangweth-Matzek B, et al. Repetitive transcranial magnetic stimulation in bulimia nervosa: Preliminary results of a single-centre, randomised, double-blind, sham-controlled trial in female outpatients. Psychother Psychosom. 2008;77(1):57-60.
  56. Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and metaanalysis. Can J Psychiatry. 2008;53(9):621-631.
  57. Daskalakis ZJ, Levinson AJ, Fitzgerald PB. Repetitive transcranial magnetic stimulation for major depressive disorder: A review. Can J Psychiatry. 2008;53(9):555-566.
  58. Loo CK, McFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol. 2008;11(1):131-147.
  59. Knapp M, Romeo R, Mogg A, et al. Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: A multi-centre randomised controlled trial. J Affect Disord. 2008;109(3):273-285.
  60. Institute for Clinical Systems Improvement (ICSI). Major depression in adults in primary care. ICSI Healthcare Guidelines. 12th ed. Bloomington, MN: ICSI; May 2008.
  61. Kleinjung T, Steffens T, Landgrebe M, et al. Levodopa does not enhance the effect of low-frequency repetitive transcranial magnetic stimulation in tinnitus treatment. Otolaryngol Head Neck Surg. 2009;140(1):92-95.
  62. Health Council of the Netherlands. Transcranial magnetic stimulation in psychiatry and neurology [summary]. Publication No. 2008/21. The Hague, The Netherlands: Health Council of the Netherlands; 2008.
  63. Brorrson B, Gunnarsson T, Hakanson I, et al. [Transcranial magnetic stimulation in treating depression]. SBU Report No. 192. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care (SBU); 2009.
  64. Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res. 2009;108(1-3):11-24.
  65. Khedr EM, Abo-Elfetoh N, Rothwell JC. Treatment of post-stroke dysphagia with repetitive transcranial magnetic stimulation. Acta Neurol Scand. 2009(a);119(3):155-161.
  66. Khedr EM, Rothwell JC, El-Atar A. One-year follow up of patients with chronic tinnitus treated with left temporoparietal rTMS. Eur J Neurol. 2009(b);16(3):404-408.
  67. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374(9688):491-499.
  68. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: Synthesis of recent data. Psychopharmacol Bull. 2009;42(2):5-38.
  69. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessment Program. Chicago, IL: BCBSA; 2009;24(5).
  70. California Technology Assessment Forum (CTAF). Repetitive transcranial magnetic stimulation for treatment resistant depression. A Technology Assessment. San Francisco, CA: CTAF; June 17, 2009.
  71. Hayes Inc. Evaluating the efficacy of transcranial magnetic stimulation to treat major depression. Hayes Overview. Lansdale, PA: Hayes; May 25, 2010. Available at: http://www.hayesinc.com/hayes/2010/05/25/evaluating-the-efficacy-of-transcranial-magnetic-stimulation-to-treat-major-depression/. Accessed July 8, 2010.
  72. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507-516.
  73. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373-380.
  74. Elman LB, McCluskey L. Diagnosis of amyotrophic lateral sclerosis. UpToDate [online serial]. Waltham, MA: UpToDate; January 2010.
  75. Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010;71(7):873-884.
  76. Levy SE, Mandell DS, Schultz RT. Autism. Lancet. 2009;374(9701):1627-1638.
  77. Guse B, Falkai P, Wobrock T. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: A systematic review. J Neural Transm. 2010;117(1):105-122.
  78. Kranz G, Shamim EA, Lin PT, et al. Transcranial magnetic brain stimulation modulates blepharospasm: A randomized controlled study. Neurology. 2010;75(16):1465-1471.
  79. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2010;(9):CD008208.
  80. Benninger DH, Berman BD, Houdayer E, et al. Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease. Neurology. 2011;76(7):601-609
  81. BluesCross Blueshield Technology Evaluation Center (TEC). Transcranial magneti stimulation for depression. 2011. Available at: http://www.bcbs.com/blueresources/tec/press/transcranial-magnetic.html. Accessed 5/13/2011.
  82. Gaynes BN, Lux L, Lloyd S, et al. Nonpharmacologic interventions for treatment-resistant depression in adults. Comparative effectiveness review No. 33. (Prepared by RTI International-University of North Carolina (RTI-UNC) Evidence based Practice Center under Contract No. 290-02-0016I). AHRQ Publication No. 11-EHC056-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/76/792/TRD_CER33_ 20111110.pdf. Accessed April 19, 2012.
  83. Henkin RI, Potolicchio SJ Jr, Levy LM. Improvement in smell and taste dysfunction after repetitive transcranial magnetic stimulation. Am J Otolaryngol. 2011;32(1):38-46.
  84. Meng Z, Liu S, Zheng Y, Phillips JS. Repetitive transcranial magnetic stimulation for tinnitus. Cochrane Database Syst Rev. 2011;(10):CD007946.
  85. Guo J, Zhou M, Yang M, et al. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2011;(9):CD008554.
  86. Freitas C, Mondragón-Llorca H, Pascual-Leone A. Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future. Exp Gerontol. 2011;46(8):611-627.
  87. Avenanti A, Coccia M, Ladavas E, et al. Low-frequency rTMS promotes use-dependent motor plasticity in chronic stroke: A randomized trial. Neurology. 2012;78(4):256-264.
  88. Corti M, Patten C, Triggs W. Repetitive transcranial magnetic stimulation of motor cortex after stroke: A focused review. Am J Phys Med Rehabil. 2012;91(3):254-270.
  89. Steeves T, McKinlay BD, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: Behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation. Can J Psychiatry. 2012;57(3):144-151.
  90. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: New clinical, neurobiological, and treatment perspectives. Lancet. 2012;379(9820):1045-1055.
  91. Leung A, Donohue M, Xu R, et al. rTMS for suppressing neuropathic pain: A meta-analysis. J Pain. 2009;10(12):1205-1216.
  92. Schneider SA, Pleger B, Draganski B, et al. Modulatory effects of 5Hz rTMS over the primary somatosensory cortex in focal dystonia -- an fMRI-TMS study. Mov Disord. 2010;25(1):76-83.
  93. Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology 2011; 64(3):163-169.
  94. Szaflarski JP, Vannest J, Wu SW, et al. Excitatory repetitive transcranial magnetic stimulation induces improvements in chronic post-stroke aphasia. Med Sci Monit. 2011;17(3):CR132-CR139.
  95. Short EB, Borckardt JJ, Anderson BS, et al. Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: A randomized, controlled pilot study. Pain. 2011;152(11):2477-2484.
  96. Peng Z, Chen XQ, Gong SS. Effectiveness of repetitive transcranial magnetic stimulation for chronic tinnitus: A systematic review. Otolaryngol Head Neck Surg. 2012;147(5):817-825.
  97. Plewnia C, Vonthein R, Wasserka B, et al.  Treatment of chronic tinnitus with theta burst stimulation: A randomized controlled trial. Neurology. 2012;78(21):1628-1634.
  98. Triggs WJ, Hajioff D. Transcranial magnetic stimulation for tinnitus: No better than sham treatment? Neurology. 2012;78(21):1624-1625.
  99. Slotema CW, Aleman A, Daskalakis ZJ, Sommer IE. Meta-analysis of repetitive transcranial magnetic stimulation in the treatment of auditory verbal hallucinations: Update and effects after one month. Schizophr Res. 2012;142(1-3):40-45.
  100. Hsu WY, Cheng CH, Liao KK, et al. Effects of repetitive transcranial magnetic stimulation on motor functions in patients with stroke: A meta-analysis. Stroke. 2012;43(7):1849-1857.
  101. Plow EB, Pascual-Leone A, Machado A. Brain stimulation in the treatment of chronic neuropathic and non-cancerous pain. J Pain. 2012;13(5):411-424.
  102. Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Bernabeu M, et al. Noninvasive brain stimulation in traumatic brain injury. J Head Trauma Rehabil. 2012;27(4):274-292.
  103. Kakuda W, Abo M, Shimizu M, et al. A multi-center study on low-frequency rTMS combined with intensive occupational therapy for upper limb hemiparesis in post-stroke patients. J Neuroeng Rehabil. 2012a;9(1):4.
  104. Kakuda W, Abo M, Momosaki R, et al. Combined therapeutic application of botulinum toxin type A, low-frequency rTMS, and intensive occupational therapy for post-stroke spastic upper limb hemiparesis. Eur J Phys Rehabil Med. 2012b;48(1):47-55.
  105. Ayache SS, Farhat WH, Zouari HG, et al. Stroke rehabilitation using noninvasive cortical stimulation: Motor deficit. Expert Rev Neurother. 2012;12(8):949-972.
  106. Corti M, Patten C, Triggs W. Repetitive transcranial magnetic stimulation of motor cortex after stroke: A focused review. Am J Phys Med Rehabil. 2012;91(3):254-270.
  107. Berlim MT, Van den Eynde F, Jeff Daskalakis Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: A meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology. 2013;38(4):543-551.
  108. Wong IS, Tsang HW. A review on the effectiveness of repetitive transcranial magnetic stimulation (rTMS) on post-stroke aphasia. Rev Neurosci. 2013;24(1):105-114.
  109. Marlow NM, Bonilha HS, Short EB. Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: A systematic review. Pain Pract. 2013;13(2):131-145.
  110. Shirota Y, Ohtsu H, Hamada M, et al; Research Committee on rTMS Treatment of Parkinson's Disease. Supplementary motor area stimulation for Parkinson disease: A randomized controlled study. Neurology. 2013;80(15):1400-1405.
  111. Awad BI, Carmody MA, Zhang X, et al. Transcranial magnetic stimulation after spinal cord injury. World Neurosurg. 2013 Jan 12. [Epub ahead of print]

Cranial Electrical Stimulation:

  1. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Electrosleep Therapy (30.4). Medicare Coverage Database. Baltimore, MD: CMS; undated.
  2. Solomon S, Guglielmo KM. Treatment of headache by transcutaneous electrical stimulation. Headache. 1985;25(1):12-15.
  3. Solomon S, Elkind A, Freitag F, et al. Safety and effectiveness of cranial electrotherapy in the treatment of tension headache. Headache. 1989;29(7):445-450.
  4. Klawansky S, Yeung A, Berkey C, et al. Meta-analysis of randomized controlled trials of cranial electrostimulation: Efficacy in treating selected psychological and physiological conditions. J Nervous Mental Dis. 1995;183(7):478-484.
  5. Pickworth WB, Fant RV, Butschky MF, et al. Evaluation of cranial electrostimulation therapy on short-term smoking cessation. Biol Psychiatry. 1997;42(2):116-121.
  6. Cameron M, Lonergan E, Lee H. Transcutaneous electrical nerve stimulation (TENS) for dementia. Cochrane Database Syst Rev. 2003;(3):CD004032.
  7. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev. 2004;(3):CD001878.
  8. Rose KM, Taylor AG, Bourguignon C, et al. Cranial electrical stimulation: Potential use in reducing sleep and mood disturbances in persons with dementia and their family caregivers. Fam Community Health. 2008;31(3):240-246.
  9. Rose KM, Taylor AG, Bourguignon C. Effects of cranial electrical stimulation on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer's disease. Appl Nurs Res. 2009;22(2):119-125.
  10. Benninger DH, Lomarev M, Lopez G, et al. Transcranial direct current stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(10):1105-1111.
  11. Plow EB, Obretenova SN, Halko MA, et al. Combining visual rehabilitative training and noninvasive brain stimulation to enhance visual function in patients with hemianopia: A comparative case study. PM R. 2011;3(9):825-835.

Navigated Transcranial Magnetic Stimulation:

  1. Picht T, Schmidt S, Brandt S, et al. Preoperative functional mapping for rolandic brain tumor surgery: Comparison of navigated transcranial magnetic stimulation to direct cortical stimulation. Neurosurgery. 2011;69(3):581-588.
  2. Picht T, Schulz J, Hanna M, et al. Assessment of the influence of navigated transcranial magnetic stimulation on surgical planning for tumors in or near the motor cortex. Neurosurgery. 2012;70(5):1248-1256.
  3. Krieg SM, Shiban E, Buchmann N, et al. Utility of presurgical navigated transcranial magnetic brain stimulation for the resection of tumors in eloquent motor areas. J Neurosurg. 2012;116(5):994-1001.
  4. Frey D, Strack V, Wiener E, et al. A new approach for corticospinal tract reconstruction based on navigated transcranial stimulation and standardized fractional anisotropy values. Neuroimage. 2012;62(3):1600-1609.
  5. Tarapore PE, Tate MC, Findlay AM, et al. Preoperative multimodal motor mapping: A comparison of magnetoencephalography imaging, navigated transcranial magnetic stimulation, and direct cortical stimulation. J Neurosurg. 2012;117(2):354-362.
  6. Forster MT, Senft C, Hattingen E, et al. Motor cortex evaluation by nTMS after surgery of central region tumors: A feasibility study. Acta Neurochir (Wien). 2012;154(8):1351-1359.
  7. Makela JP, Vitikainen AM, Lioumis P, et al. Functional plasticity of the motor cortical structures demonstrated by navigated TMS in two patients with epilepsy. Brain Stimul. 2012 May 23. [Epub ahead of print]


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top